Graduate Theses, Dissertations, and Problem Reports
2019

Role of Extracellular Vesicles in Neuroinflammatory Progression
and Mitochondrial Functional Alterations
Ashley E. Russell
West Virginia University, aekerr@mix.wvu.edu

Follow this and additional works at: https://researchrepository.wvu.edu/etd
Part of the Molecular and Cellular Neuroscience Commons

Recommended Citation
Russell, Ashley E., "Role of Extracellular Vesicles in Neuroinflammatory Progression and Mitochondrial
Functional Alterations" (2019). Graduate Theses, Dissertations, and Problem Reports. 3947.
https://researchrepository.wvu.edu/etd/3947

This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

Role of Extracellular Vesicles in Neuroinflammatory Progression
and Mitochondrial Functional Alterations
Ashley E. Russell

A dissertation submitted to the West Virginia University Health Science Center
Neuroscience Program in partial fulfillment of the requirements for the degree of:

Doctor of Philosophy in Neuroscience

James W. Simpkins, Ph.D., Chair
Candice M. Brown, Ph.D.
Werner J. Geldenhuys, Ph.D.
Rosana Schafer, Ph.D.
Gregory Konat, Ph.D.

WVU Neuroscience Program
Morgantown, West Virginia
2019

Keywords: Neuroinflammation, microRNAs, Extracellular Vesicles, Mitochondria

Copyright 2019 Ashley E. Russell

ABSTRACT
Role of Extracellular Vesicles in Neuroinflammatory Progression and Mitochondrial
Functional Alterations

Ashley E. Russell

Inflammation within the central nervous system (CNS), termed neuroinflammation, is a defining
characteristic of many neuropathological conditions, including Alzheimer’s disease (AD) and
stroke. Certain inflammatory mediators activate the transcription factor NF-κB, which induces
transcription of many pro-inflammatory genes, including miR-34a and miR-146a. Several target
candidate genes of these miRNAs encode for proteins of the mitochondrial electron transport
chain. In our studies, we demonstrate that in response to inflammatory stimuli, such as TNF-α,
the expression of miR-34a and -146a is significantly increased in several CNS cell types, and in
their secreted extracellular vesicles (EVs). Exposure to TNF-α-derived EVs significantly
increases cellular bioenergetics in naïve recipient cells, with a concurrent increase in reactive
oxygen species, indicative of impaired mitochondrial function. Further, using an animal model of
experimental transient middle cerebral artery occlusion, we assess the effects of intermittent
systemic LPS exposure, with long recovery periods, on stroke infarct volume. Relative to saline
controls, animals repeatedly exposed to LPS have significantly larger cortical infarcts, and lower
mRNA expression of autophagy genes. Inflammation-induced reduction in autophagy may lead
to post-stroke increases in apoptosis. Together, these data suggest that the modulation of miR146a and miR-34a in response to neuroinflammatory stimuli may mediate the loss of
mitochondrial integrity and function of cells, and that EVs significantly impair mitochondrial
function in recipient cells. Further, intermittent systemic inflammation significantly alters the
neuroinflammatory response within the brain, leading to increased stroke infarct volumes.
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Chapter 1

Introduction
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1.1 Introduction to Inflammation
Inflammation is an evolutionary adaptation designed to protect organisms from pathogenic
infections, remove and restore damaged tissue after injury, and eliminate mutated cells.
Organisms must be able to regulate and balance the immune response to allow for the clearance
of pathogens and damaged tissue, while restricting the death of healthy cells. Unfortunately, the
immune system is not perfect and a multitude of things can go awry, giving rise to ailments such
as autoimmune diseases, cancers, and chronic inflammation.

The immune system is subdivided into two arms comprised of the innate and adaptive systems.
While the adaptive branch of the system allows for highly specific recognition of non-self
antigens, the innate arm operates on a more general level of detection, surveying the environment
for highly conserved structural motifs present on many pathogenic invaders. This is due to the
expression of pattern recognition receptors (PRRs) on innate immune cells, which can detect
both pathogen associated molecular patterns (PAMPs) expressed on microorganisms like
bacteria, and damage associated molecular patterns (DAMPs), which are altered or damaged
endogenous ligands, usually released by necrotic, senescent, and/or damaged cells. Among
PRRs, toll-like receptors (TLRs) play a central role in the progression of inflammation (Kielian,
2006; Takeda et al., 2003) since their engagement triggers a potent immune signaling pathway;
activation of the family of transcription factors, nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB) (Oeckinghaus and Ghosh, 2009; Kawasaki and Kawai, 2014).

A. NF-κB signaling
Initially discovered in the Drosophila, TLRs participate in the immune response by recognizing
specific molecular patterns. To date, 10 human and 12 murine TLRs have been described, each
of which recognizes and responds to different molecular patterns (Kawasaki and Kawai, 2014).
For example, TLR4 recognizes lipopolysaccharide (LPS; also referred to as endotoxin), which is
one of the main constituents of Gram-negative bacterial cell walls, while TLR3 recognizes
double-stranded RNA (dsRNA), characteristic of viruses. Some TLRs are expressed on the cell
surface (e.g. TLR4) and participate in identifying microbial membrane components, while other
2

TLRs (e.g. TLR3) are expressed on intracellular compartments, such as endosomes, and mostly
recognize microbial or viral nucleic acids (Kawai and Akira, 2010). Upon their activation, an
intracellular signaling cascade is initiated, eventually leading to the activation of NF-κB.
The NF-κB complex refers to a family of five Rel proteins expressed in nearly all cell types and
tissues. These proteins can homo- or heterodimerize, and upon activation, translocate to the
nucleus to bind with specific promotor/enhancer regions of DNA; thus NF-κB plays a prominent
role in altering gene transcription in response to various stimuli (Oeckinghaus and Ghosh, 2009).
The two major pathways by which NF-κB can be activated are the canonical, and the alternative
(noncanonical) pathways. TLRs or tumor necrosis factor-alpha receptor (TNFR) activation can
activate the canonical pathway. Briefly, within the cytoplasm, the NF-κB complex is sequestered
by the inhibitor of κB (IκB), which prevents the complex from exerting any transcriptional
effects. Activation of the canonical pathway initiates the inducible degradation of IκB via its
phosphorylation by IκB kinase (IKK), and thus targeting it for ubiquitination and eventual
degradation by the proteasome (Karin and Delhase, 2000). NF-κB is subsequently translocated to
the nucleus and activates the transcription of dozens of genes, whose functions range from cellproliferation and anti-apoptotic mechanisms, to transcription of immunomodulators, such as
chemokines and cytokines, including tumor necrosis factor-alpha (TNF-α) (Oeckinghaus and
Ghosh, 2009; Pahl, 1999).

B. TNF-α Synthesis and Signaling
Carswell and colleagues identified a serum factor that induced tumor necrosis, later termed TNFα (Carswell et al., 1975). After decades of research, it has been established that TNF-α is
responsible for more than just initiating tumor cell death; its signaling is a highly complex
process that plays a key role in the immune response. Interestingly, TNF-α is produced in
response to NF-κB activation, and its signaling also activates NF-κB; as such, the
proinflammatory cytokine TNF-α is a major player in the progression of inflammation.
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TNF-α is a member of the TNF superfamily, which includes 19 ligands, all of which signal
through at least one of the 29 TNF-receptors (TNFRs) (MacEwan, 2002; Aggarwal, 2003;
Wajant et al., 2003; Montgomery and Bowers, 2012). The ligands of the TNF superfamily are
capable of inducing cellular proliferation, differentiation, survival, and apoptosis (Aggarwal,
2003). TNF-α is produced by a variety of cell types including most immune cells, endothelial
cells, microglia, astrocytes, and neurons (Montgomery and Bowers, 2012), and signals through
TNFR1 expressed on all nucleated cells, and TNFR2, expressed on immune, endothelial, and
nervous system cells (MacEwan, 2002; Aggarwal, 2003; Montgomery and Bowers, 2012).
TNF-α expression is regulated at the transcriptional, post-transcriptional, and translational level,
dependent upon stimulation by pathogens, injury, and immune activation (Montgomery and
Bowers, 2012). TNF-α mRNA translation results in a 26-kDa transmembrane-associated integral
protein: tmTNF (also referred to as pro-TNF-α), generally organized in stable homotrimers
(MacEwan, 2002; Wajant et al., 2003; Montgomery and Bowers, 2012). TNF-α converting
enzyme (TACE) can cleave tmTNF protein to a 51-kDa soluble trimeric form, sTNF, better
known as TNF-α (MacEwan, 2002; Wajant et al., 2003; Montgomery and Bowers, 2012).

Understanding the difference between the two forms of TNF (tmTNF and sTNF) and how they
exert their signaling pathways is of utmost importance. sTNF has a high affinity for TNFR1 and
a slow dissociation period, while tmTNF has a high affinity for TNFR2 (MacEwan, 2002;
Montgomery and Bowers, 2012). TNFR1 and TNFR2 are not enzymatically active themselves.
These receptors must form homotrimers and associate with intracellular adaptor proteins referred
to as TNF receptor-association factors (TRAFs), to induce intracellular signaling pathways upon
receptor activation; TRAFs are signal transducers for TNF-α and its receptors (TNFR1 &
TNFR2) (MacEwan, 2002).

Signaling through TNFR1 leads to the formation of two complexes, which lead to the activation
of NF-κB or apoptosis, respectively (Micheau and Tschopp, 2003). On the cytoplasmic portion
of the TNFR1 is a death domain (DD), which is usually blocked by the silencer of death domain
(SODD) protein. When the receptor is activated by binding of TNF-α, within seconds SODD
4

dissociates and allows TRADD (TNF receptor-associated death domain) and receptor interacting
serine/threonine kinase 1 (RIP1) to interact with the DD (MacEwan, 2002). TRAF2/5 indirectly
interacts with TNFR1 by associating with TRADD. This signaling complex of proteins is
referred to as complex I, and its formation leads to activation of NFκB (Micheau and Tschopp,
2003). TRAF2/5 activates NFκB-inducing kinase (NIK) which phosphorylates the inhibitor of
κB kinase (IKK), which then leads to the activation of NFκB (MacEwan, 2002) as described in
the previous section. As activation of NF-κB can lead to the transcription of anti-apoptotic genes
(e.g. the caspase-8/10 inhibitor, cFLIP), signaling through formation of complex I only does not
result in the activation of apoptosis (Ting and Bertrand, 2016). Formation of complex II occurs
more transiently, as it requires dissociation of TRADD from complex I and subsequent
association with Fas associated via death domain (FADD) (Ting and Bertrand, 2016). This
complex recruits and activates caspase-8/10, which successively activates caspase-3 and leads to
initiation of apoptosis (MacEwan, 2002; Micheau and Tschopp, 2003).

TNFR2 lacks the DD associated with TNFR1 and has the capacity to directly interact with
TRAF2 under some conditions (MacEwan, 2002). This interaction allows for the recruitment of
receptor-interacting protein (RIP) and Fas-associated death domain (FADD), which contains a
death effector domain (DED) (MacEwan, 2002). This complex can associate with, and activate
caspases (namely caspase-8) and lead to cellular apoptosis, or activation of NF-κB, leading to
alterations in gene transcription (MacEwan, 2002). Other signaling pathways associated with
TNFR2 are not yet fully understood; more is known about TNFR1 pathway activation.
TNF-α is a key regulator of the immune response, low levels of TNF-α promotes the swift
initiation of defense responses to inflammatory stimuli, however high levels of TNF-α can lead
to chronic inflammation and tissue damage (Tracey et al., 2008). Aberrant signaling of this
molecule has been implicated in many systemic inflammatory diseases, such as Crohn’s and
various types of arthritis (Bradley, 2008; Tracey et al., 2008), and has also been shown to be
upregulated in the brains of patients suffering from neuroinflammatory diseases (Montgomery
and Bowers, 2012).
5

Aside from its role in inflammation, TNF-α has also been implicated in neuronal proliferation,
even into adulthood. Adult neurogenesis occurs within only two regions of the brain; the
subventricular zone (SVZ) lining the lateral ventricles and the subgranular zone (SGZ) of the
dentate gyrus (which is part of the hippocampus thought to be responsible for the formation of
episodic memories). Injury and inflammation can modulate the formation of new cells within
these regions which can migrate to the site of injury (Wu et al., 2000; Heldmann et al., 2005;
Widera et al., 2006). These proliferating progenitor cells express TNF-α and its receptors
(Bernardino et al., 2008; Keohane et al., 2010), raising the possibility that in these cells TNF-α
signaling is occurring in both paracrine and autocrine manners (Heldmann et al., 2005). The role
of TNF-α in this process however, remains yet to be fully elucidated as various labs report
conflicting data. Some reports suggest that exogenous administration of TNF-α induces cellular
proliferation within the rat SVZ (Wu et al., 2000; Bernardino et al., 2008), while others find that
TNF-α administration reduces progenitor cell number, alters neuron morphology, and increases
astrocytes and glia (Neumann et al., 2002; Monje et al., 2003; Golan et al., 2004; Liu et al., 2005;
Keohane et al., 2010). Inhibition of adult hippocampal neurogenesis has negative consequences
on hippocampal-dependent tasks, such as learning temporal associations, suggesting the
formation of these types of associations and memories require the development and integration
of newly born neurons (Shors et al., 2001). Patients suffering from Alzheimer’s disease (AD)
struggle with forming new memories and correctly recalling old ones, both of which are
hippocampal dependent functions. As will be discussed in a later section, AD is considered a
chronic neuroinflammatory disease, and levels of TNF-α are upregulated in patient brains
(Sharma et al., 2012), thus furthering the possibility that TNF-α negatively influences adult
neurogenesis.
TNF-α is just one of many cytokines critically involved in the initiation and progression of the
immune response. Activation of pathways that alter gene transcription, like NF-κB, play major
roles in the complex process of inflammatory initiation, progression, and resolution. At the posttranscriptional level, other regulators such as microRNAs can come into play and alter
inflammatory signaling and disease status.
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1.2 microRNAs
MicroRNAs (miRNAs) are small (~22 nucleotides), non-coding RNAs that play important
regulatory roles as gene repressors (Chen and Rajewsky, 2007; Ha and Kim, 2014; Kim, 2005).
They function by base pairing to complementary sites within the 3’ untranslated region (UTR) of
mRNAs, which inhibits translation or leads to the decapping of the 5’ mRNA, thus targeting the
mRNA for degradation (Rehwinkel et al., 2005; Ha and Kim, 2014). Perfect miRNA basepairing with mRNA is not necessary; candidate target sites for miRNA-mRNA interaction
require ~6-8 nucleotides in the 5’ region of the miRNA and the 3’ UTR of the mRNA to pair
(Doench and Sharp, 2004; Krek et al., 2005). Because of this, miRNAs can be a tad promiscuous
in their inhibitory functioning; a single miRNA can target approximately 200 mRNAs (Krek et
al., 2005). Similarly, a single mRNA can be targeted by several miRNAs, and it is thought that
approximately 30% of human genes can be regulated by miRNAs (Lewis et al., 2005).

RNA polymerase II or III (Pol II/III) transcribe miRNA genes as long primary transcripts (~1kb)
termed pri-miRNAs; these contain a hairpin structure in which the mature miRNA sequence
resides (Ha and Kim, 2014). Within the nucleus, Drosha and DGCR8 form a microprocessor
COMPLEX, which cleaves the hairpin structure (~65 nucleotides), giving rise to a pre-miRNA
(Ha and Kim, 2014). Exportin 5 assists with the translocation of the pre-miRNA into the
cytoplasm, where Dicer cleaves the pre-miRNA near the terminal loop, creating a doublestranded RNA molecule (Ha and Kim, 2014). Next, the guide strand of the RNA duplex is
preferentially loaded onto an Argonaute (AGO) protein, and the passenger strand of RNA
(miRNA*) is removed, allowing for the formation of a mature RNA-induced silencing complex
(RISC) (Ha and Kim, 2014). The RISC is now capable of targeting complementary mRNAs;
near perfect complementarity generally results in RNA slicing (Tolia and Joshua-Tor, 2007),
while imperfect complementarity results in translational repression via the blockage of proteinprotein interactions (Iwasaki et al., 2009) or by decapping the mRNA, followed by subsequent
degradation (Rehwinkel et al., 2005; Behm-Ansmant et al., 2006).

miRNAs are involved in many important cellular functions, and alterations in their expression
are associated with numerous diseases by altering protein expression. A mounting body of
7

evidence documents a large number of miRNAs are involved in regulating inflammation. For
example, in normal physiological conditions, transcription of miR-146a, miR-155, and miR-21
remain at low levels. However activation of TLRs results in strong NF-κB-dependent induction
and subsequent upregulation of these miRNAs (Taganov et al., 2006; Olivieri et al., 2013; Rippo
et al., 2014). Further, several components of TLR signaling are targeted by these miRNAs,
suggesting their complex role in regulating the inflammatory cascade (Quinn and O’Neill, 2011).

1.3 Extracellular Vesicles
An interesting point of discussion is that miRNAs are not confined to the cell IN which they
were transcribed; they can be secreted out of one cell and taken up by another. This mechanism
is usually mediated by extracellular vesicles (EVs). The study of EVs is a newly emerging,
exciting area of research, and over the past three and a half decades, the field has progressed
substantially. The first description of EVs occurred in the early 1980’s; within a week of one
another, two seminal papers from independent labs were published, describing the release of
transferrin receptors from maturing reticulocytes via externalized vesicles (Harding and Stahl,
1983; Pan and Johnstone, 1983). The exosome release pathway (which will be described in the
following section) was first described in the same year (Harding et al., 1983, 1984). EVs were
originally thought of “garbage bags” by which cells packaged and disposed of unwanted
materials (e.g. unnecessary transferrin receptors) (Pan et al., 1985; Johnstone et al., 1987). With
time, and increasing interest from other research areas, EVs began to be viewed as more than just
waste disposal units. Today, scientists from virtually every area of biological research are
becoming involved in the study of EVs, with cancer, immunology, and neuroscience being some
of the largest areas of ongoing EV research.

A. What Are EVs?
EVs are small, nanosized (< 2 μm), membrane-bound vesicles shed (or secreted) by most, if not
all cell types into the extracellular environment. The term “EV” generally refers to three distinct
subpopulations of vesicles, each with specific membrane compositions and unique biogenesis
8

pathways. Apoptotic bodies are formed by cells undergoing apoptosis; these vesicles are large
(500 – 2,000 nm) and express high amounts of phospatidyl-serine, which can act as an “eat me”
signal to macrophages (Lee et al., 2012a; Segawa and Nagata, 2015), and will not be discussed in
further detail. Microvesicles (MVs; sometimes referred to as ectosomes) are shed from the
outward budding of the plasma membrane. These vesicles are slightly smaller in size (100 –
1,000 nm), and express integrins, selectins, and CD40 ligands (Lee et al., 2012a; Raposo and
Stoorvogel, 2013). Lastly, exosomes, which are the smallest type of EV (40 – 100 nm), are
derived from the endosomal pathway.

Biogenesis of exosomes is much more complicated than that of apoptotic bodies or MVs.
Briefly, as an early endosome matures to a late endosome, its membrane begins to bud inwards,
creating intraluminal vesicles (ILVs) in the process, and transforming into what is now
considered a multivesicular body (MVB) (Stoorvogel et al., 1991). MVBs can fuse with
lysosomes and their contents are degraded. Alternatively, MVBs can fuse with the cell’s plasma
membrane, thus releasing their ILVs into the extracellular environment, giving rise to exosomes.
As these vesicles undergo several processing steps, they express specific proteins which assist in
the formation of multivesicular bodies (e.g. ALIX, TSG101), proteins involved in membrane
transport and fusion (annexins, flotillin, Rab proteins), and the canonical exosome proteins
CD63, CD81, CD9 (Lee et al., 2012). It is now thought that prior to packaging ILVs, late
endosomes are destined for one fate or another, and that cells can host different subpopulations
of MVBs (White et al., 2006). This however, depends on several factors including their location
within the cell (Buschow et al., 2005), the stimulatory factor inducing fusion with lysosomes or
plasma membrane, (Wubbolts et al., 2003), and where in the maturation processes a cell is
(Colombo et al., 2014).

EVs function as cell-to-cell communicators, transferring information from one cell to another.
Indeed, the RNA and protein cargo within EVs is functional and can exert effects on recipient
cells. The first evidence of the horizontal transfer of proteins via extracellular vesicles was found
nearly two decades ago (Mack et al., 2000; Baj-Krzyworzeka et al., 2002; Rozmyslowicz et al.,
2003; Janowska-Wieczorek et al., 2005). Not long after, EV-mediated horizontal transfer of
9

mRNA and miRNA was demonstrated (Valadi et al., 2007). Transferred mRNAs could be
translated into proteins, and miRNAs were able to function as translational repressors (Lotvall
and Valadi, 2007; Colombo et al., 2014).

It is thought that while both exosomes and MVs contain functional proteins and RNAs of the
parent cell from which they are derived, exosomal cargo has been specifically, and deliberately,
packaged for secretion from the cell (McKenzie et al., 2016). Indeed, there is some evidence
suggesting that there are highly specific sorting pathways for the packaging of exosomal cargo
(Ramachandran and Palanisamy, 2012). The endosomal sorting complex required for transport
(ESCRT) consists of four complexes (ESCRT-0, -I, -II, and –III), and is comprised of a family of
approximately thirty proteins (Hanson and Cashikar, 2012). Each of the four ESCRT complexes
can play a role in selectively packaging proteins and RNAs into ILVs within the endosome.
ESCRT complexes -0, -I, and –II directly bind to ubiquinated proteins, and load them into ILVs
(Hislop and von Zastrow, 2011). In addition to sorting ILV contents, ESCRT complexes
influence the budding and cleavage of the endosomal membrane, thus giving way to the
formation of ILVs (Gupta and Pulliam, 2014). While the ESCRT complexes have a large role in
ILV formation, MVBs containing ILVs are still formed, even in the absence/inactivation of
ESCRT (Stuffers et al., 2009), indicating the presence of an ESCRT-independent cargo-sorting
pathway (Trajkovic et al., 2007).

Areas of the endosomal limiting membrane that become enriched in membrane spanning
proteins, known as tetraspanins are referred to as Tetraspanin-enriched membrane domains
(TEMs). These areas are often required for proper fission/fusion of vesicles as they begin to bud
inwards on the endosomal membrane, thus also contributing to the formation of ILVs (Hemler,
2008). CD63 is a tetraspanin that is highly abundant on ILVs, and has been shown to play a role
in the sorting of some proteins (van Niel et al., 2011). Additionally, neutral sphingomyelinase
(Trajkovic et al., 2008) and phospholipase D2 (Ghossoub et al., 2014) are both lipid metabolism
enzymes which have been shown to induce inward budding of the late endosomal limiting
membrane, thus creating ILVs.
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The small GTPases Rab27a and Rab27b also play critical roles in exosome formation and
secretion (Ostrowski et al., 2010; Alexander et al., 2017). The Arrestin domain-containing
protein 1 (ARRDC1) has been shown to significantly affect the biogenesis and secretion of
exosomes, and also mediate the release of a subpopulation of MVs derived from the plasma
membrane (Nabhan et al., 2012; Mackenzie et al., 2016; Wang and Lu, 2017; Anand et al.,
2018). Several groups have shown highly variable expression patterns in cells and their cognate
EVs, which may be due to specificity of cargo sorting (Batagov et al., 2011; Montecalvo et al.,
2012; Cha et al., 2015; McKenzie et al., 2016; Hinger et al., 2018).

Alternatively, MV cargo is likely packaged in a more coincidental manner and is reflective of the
parental cell’s cytoplasmic components near the plasma membrane at the time of shedding.
Indeed, the RNA profile of large vesicles reveals more similarity than small vesicles to the cell
from which they are derived (Wei et al., 2017). This however, may be a result solely based on
vesicle size, as larger vesicles may incorporate full-length mRNAs into their lumen more easily
than smaller EVs.

B. EVs and Inflammation
Evidence also suggests a role of inflammation in EV biogenesis and secretion (Théry et al.,
2009). In response to TNF-α or interferon-gamma (IFN-γ) exposure, EVs released from
mesenchymal stem cells contained very different protein and RNA profiles, compared to
unstimulated control cells (Harting et al., 2018). Similarly, after LPS exposure, dendritic cells
released significantly more EVs compared to EV concentrations released from unstimulated cells
(Obregon et al., 2006). Further, dsDNA-induced inflammation also increases EV release
(Takahashi et al., 2017), and endosomes expressing activated TLRs may also lead to inducible
EV release (Srinivasan et al., 2017). Another group has also demonstrated that EVs express
major histocompatibility complex I (MHCI) and MHCII, along with surface antibodies; therefore
it is expected that these EVs are directly participating in the immune response (Utsugi-Kobukai
et al., 2003; Luketic et al., 2007; Saunderson et al., 2008; Bobrie et al., 2011; Chaput and Théry,
2011). Recently, it has been shown that EVs may be targeted to inflamed tissue (Balusu et al.,
11

2016). Together, these data demonstrate that inflammatory stimuli can alter EV cargo and
number, and these vesicles can act as immunomodulatory signaling molecules. These findings
are not restricted to the peripheral immune response as EVs have been shown to also participate
in neuroinflammation.

1.4 Neuroinflammation
Inflammation within the brain, termed neuroinflammation, can stem from within the central
nervous system (CNS) or be induce via systemic inflammation. Due to the selective permeability
of the blood-brain barrier (BBB), the CNS was previously considered “immune privileged”,
however, the CNS is indeed vulnerable to systemically-derived bacterial, viral, and autoimmune
insult, and accumulating evidence supports the notion of highly complex immune-nervous
system interactions (Galea et al., 2007).

A. The Role of the Blood-Brain-Barrier
The vasculature in some areas in the CNS (circumventricular organs, ventricles, choroid plexus,
and meninges) is characterized by large fenestrations between endothelial cells, similar to
peripheral vasculature (Meisel et al., 2005). There is direct communication between the CNS and
circulating blood in these regions (Dermietzel and Leibstein, 1978; Prat et al., 2001), and due to
a high concentration of cytokine receptors, they are well equipped for sensing changes in
peripherally circulating cytokine levels (Haddad et al., 2002). Consequently, immune responses
induced here are similar to those that occur in the periphery (Galea, 2007).

Conversely, the vascular endothelial cells that form the circulatory network for the rest of the
brain comprise the blood-brain barrier (BBB). These cells form and maintain tight junctions in
response to factors secreted by glial cells (Prat et al., 2001; Alvarez et al., 2013). The outdated
concept of CNS immune privilege stemmed from the belief that the blood-brain barrier (BBB)
was completely impenetrable, and therefore allowed the CNS to remain unaffected by systemic
inflammation. Contrary to this belief, conclusive evidence shows that while tight junctions are
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selectively permeable and provide somewhat of a physical barrier, the BBB does not serve as an
impassable blockade from all peripherally circulating factors.

During normal physiological conditions, tight junctions between endothelial cells prevent the
infiltration of unwanted cells, molecules, bacteria, and viruses into the CNS. It has been shown
that inflammation, both peripherally- and CNS-derived, can weaken the BBB. Some evidence
also suggests a potential role for miRNAs in the inflammation-induced weakening of the BBB.
Peripherally circulating cytokines can induce upregulation of miR-155 in brain endothelial cells
and lead to the disruption of tight junctions between cells (Lopez-Ramirez et al., 2014).
Neuroinflammation induced by the accumulation of amyloid β (Aβ) plaques in the brain have
been shown to reduce miR-107 expression in brain endothelial cells, and lead to disruption of the
BBB, the effects of which can be reversed upon overexpression of miR-107 (Liu et al., 2016b).
The weakening of the BBB reduces its ability to prevent infiltration of peripherally circulating
factors, such as soluble, blood-derived plasma proteins (Veerhuis, 2011), monocytes (Nottet et
al., 1996; Persidsky and Gendelman, 1997), leukocytes (Wekerle et al., 1986; Hickey et al.,
1991; Bell et al., 1996), and pathogens into the CNS, (Montagne et al., 2015). Upon infiltration,
these factors further contribute to neuroinflammation.

The concept of inflammaging posits that aging induces chronic, low-grade systemic
inflammation in the absence of overt infection, causing a shift in the immune system towards a
pro-inflammatory state (Franceschi et al., 2018). In line with this, age has also been shown to
heavily influence the permeability and functional capacity of the BBB (Prat et al., 2001; Zeevi et
al., 2010; Montagne et al., 2015). Older adults and animals experience reduced transport of key
metabolic molecules, such as glucose and choline, from the periphery into the CNS (Shah and
Mooradian, 1997), which can lead to impaired neurological functioning. Just as in heightened
inflammatory states, when the integrity of the BBB has been compromised with age, it becomes
more permeable, or leaky, allowing peripheral substances entrance into the CNS (Shah and
Mooradian, 1997).
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In order for immune cells to invade the CNS, they must first adhere to the brain endothelium;
this is mediated by cellular adhesion molecules, namely ICAM-1 and VCAM-1 expressed on
vascular ECs. In response to immunomodulatory factors that are increased during systemic
inflammation such as TNF-α, IFN-γ, and IL-1, brain microvascular ECs upregulate ICAM-1 and
VCAM-1 by 3- to 15-fold, thus enhancing immune cell invasion. These cytokines may play a
large role in the infiltration of peripherally circulating leukocytes into the CNS (Prat et al., 2001),
while also contributing to progression of the neuroinflammatory response.

B. The Role of Microglia
When foreign, peripheral substances cross the BBB, microglia (which are commonly referred to
as the resident macrophages of the CNS) become activated. Under normal physiological
conditions, microglia were long believed to be resting, or quiescent; however evidence gathered
over the past decade indicates that microglia are constantly surveying the microenvironment for
disturbances, such as protein aggregates, damaged neurons, alterations in extracellular potassium
levels, or intruders like viruses, bacteria, or peripheral immune cells (Gehrmann et al., 1995;
Davalos et al., 2005; Nimmerjahn et al., 2005; Morris et al., 2013). In response to inflammatory
stimuli, astrocytes also become activated. These specialized cells respond by forming a physical
barrier known as a glial scar, in an attempt to contain the inflammation and prevent it from
spreading to neighboring, healthy tissue (Cekanaviciute and Buckwalter, 2016).

Microglia play a pivotal role in the neuroinflammatory response (González et al., 2014). When
they become activated, they migrate towards the focal site of inflammation within minutes and
phagocytose the inflammation-inducing substance (Davalos et al., 2005; Wu et al., 2007).
Although resting-state microglia constitutively express immune regulatory markers, their
activation leads to a rapid upregulation of these cellular immune markers, such as complement
receptors and MHCII antigens, which allow them to interact with other cells in the CNS (e.g.
other microglia, neurons, astrocytes, infiltrating T-cells) (Akiyama et al., 2000b). Additionally,
activated microglia have also been shown to secrete cytokines, chemokines, complement factors,
and free radicals, which promote inflammation and help direct the immune response (Perry et al.,
14

2001; Rock et al., 2004; Tuppo and Arias, 2005). In normal conditions, acute increases of
inflammatory molecules can be beneficial as microglia remove damaged tissue or peripheral
invaders; however, exaggerated or chronic activation of microglia can induce major pathology
and neurodegeneration.

Inflammaging also appears to influence microglia and their capacity to react properly to brain
insult. With age, microglia undergo a shift towards a pro-inflammatory state, and exhibit
dysfunctional or exaggerated responses to inflammation, thus creating an unfavorable
environment for neurons (Mosher and Wyss-Coray, 2014; Koellhoffer et al., 2017). Studies
investigating the protein and RNA profiles of microglia in mice at different ages indicate that age
and sex do appear to play a role in expression patterns, and that polarization towards the
proinflammatory phenotype occurs at 12 months of age (Crain et al., 2013). Furthermore, several
“hallmarks” of aging microglia have been described, including upregulation of TLRs, proinflammatory cytokines, and increased reactivity upon stimulation (Spittau, 2017).

Aside from traditional immune interactions described above, miRNAs have also been recently
identified to play a role in microglial activation and regulation in response to inflammation
(Guedes et al., 2013). Activation of microglia to either the “pro- inflammatory” M1 (classical
activation) or “anti- inflammatory” M2 (alternative activation) phenotypes appears to be
dependent on a network of miRNAs. For example, LPS exposure shifts microglia towards the
M1 phenotype, downregulates miR-Let-7a expression, and subsequently leads to cell death (Cho
et al., 2015). Overexpression of microglial miR-Let-7a altered the phenotypic activation to M2,
reduced apoptosis and nitrite production, increased secretion of anti-inflammatory cytokines, and
enhanced production of brain-derived neurotrophic factor (BNDF) (Cho et al., 2015).
Interestingly, miR-124 is highly expressed in resting-state microglia but becomes significantly
downregulated when microglia take on the M2 phenotype(Ponomarev et al., 2011).
Overexpressing miR-124 in microglia prevents microglial activation from even occurring
(Ponomarev et al., 2011). Furthermore, miR-155 is classically regarded as a pro-inflammatory
miR, and is upregulated in M1 activated microglia after exposure to cytokines like TNF- α and
IFN-γ (Cardoso et al., 2012). This has been shown to further enhance cytokine release from
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microglial cells; however, it has also been shown to induce IFN-β secretion, which appears to
activate an anti-inflammatory pathway (Dalpke et al., 2008; Wang et al., 2010). These data
suggest that miR-155 may influence early induction of the inflammatory response, while also
acting to regulate it downstream.

C. EVs and Neuroinflammation
Some of the first studies examining the relationship between EVs and the CNS occurred in the
early 2000’s (Greco et al., 2001; Marzesco et al., 2005; Fauré et al., 2006). Since then, several
groups have shown that EVs participate in the spread of pathology within the brain (Vella et al.,
2008), including the transfer of prions (Fevrier et al., 2005), Aβ (Rajendran et al., 2006; Aguzzi
and Rajendran, 2009), and tau (Saman et al., 2012; Wang et al., 2017b), sparking the interest in
investigating the role of EVs in disease progression. As such, it is necessary to elucidate the
underlying mechanisms which are responsible for inducing EV-mediated spread of these
pathological molecules, how uptake of these EVs affect recipient cells, and how these outcomes
differ in various CNS cell types.

Glial cells play significant roles in maintaining CNS homeostasis, regulating neuroinflammation,
and supporting neurons, etc. Unsurprisingly, much of the focus of EV research in the realm of
neuroscience has been centered on investigating the role of astrocyte (Bianco et al., 2009; Goetzl
et al., 2016, 2018; Lafourcade et al., 2016; Luarte et al., 2017; Willis et al., 2017; Xin et al.,
2017), microglial (Bianco et al., 2005; Potolicchio et al., 2005; Antonucci et al., 2012; Turola et
al., 2012; Glebov et al., 2015), and oligodendrocyte (Krämer-Albers et al., 2007; Frühbeis et al.,
2013) derived vesicles, and how these EVs may affect recipient neurons. Interestingly, like EVs
derived from systemic immune cells, those secreted by microglia contain MHCII receptors and
participate in the immune response (Potolicchio et al., 2005; Verderio et al., 2012).
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1.5 Mitochondria
The brain accounts for approximately 2% of the body’s total weight, yet consumes 20% of the
body’s energy. Over half of this energy is required for powering and maintaining the
sodium/potassium pump required for maintaining the membrane potential in neurons.
Mitochondria are the powerhouses of the cell, and neurons critically depend on glucose
metabolism and oxidative phosphorylation to meet these high energy demands, as they have no
form of energy storage (Falkowska et al., 2015). Astrocytes have energy stores which can be
tapped when glucose levels are low (Cataldo and Broadwell, 1986; Baltan, 2015); via the
shuttling of lactate from astrocytes to neurons, which may be mediated by astrocyte-derived EVs
containing monocarboxylate transporter 1 (Potolicchio et al., 2005), neurons can convert the
donated lactate to pyruvate to be utilized in oxidative phosphorylation (Riske et al., 2017).
Disruptions in neural energy metabolism can reduce ATP production, which even transiently,
can have profound effects on neuronal viability (Simpkins et al., 2010).

Not only are mitochondria responsible for supplying the main source of energy for most cells,
adenosine triphosphate (ATP), these organelles also play important roles in the cell, including
signaling through reactive oxygen species (ROS) and the induction of apoptosis. Mitochondria
are the main source of ROS (Balaban et al., 2005). Superoxide and hydrogen peroxide (H2O2) are
typical byproducts of mitochondrial oxidative phosphorylation as electrons are shuttled down the
electron transport chain (ETC). Environmental factors, including TNF-α (Shoji et al., 1995;
Corda et al., 2001) and hypoxia (Guzy et al., 2005) can increase mitochondrial ROS production.
These reactive molecules can induce oxidative stress by damaging DNA, lipids, and proteins,
which can lead to cellular dysfunction and/or death (Gupta et al., 2012). High levels of ROS and
can also alter NF-κB signaling, thereby modulating the immune response (Toledano et al., 1993;
Kabe et al., 2005). Mitochondria can participate in the immune response through several other
avenues. For example, various cytosolic PRRs can bind with mitochondrial antiviral signaling
proteins (MAVS) expressed on the outer mitochondrial membrane, which can lead to the
induction of NFκB activation (Meyer et al., 2018). Damaged or stressed mitochondria can leak
mitochondrial DNA (mtDNA) into the cytoplasm of the cell and be sensed as a DAMP, which
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can also induce NF-κB activation (Collins et al., 2004). Improperly functioning mitochondria can
be extremely detrimental to cells by producing oxidative stress, or by inducing sterile
inflammation.

Apoptosis is also regulated by mitochondria via downstream activation of caspases. The B-cell
lymphoma 2 (Bcl-2) protein family consist of both pro- and anti-apoptotic proteins. The antiapoptotic proteins (BCL-2, BCL-w, BCL-xL, A1, and MCL) are localized to the outer
mitochondrial membrane (OMM), and work to inhibit the functions of the pro-apoptotic Bcl-2
proteins (including the effector proteins, BAK and BAX, and the essential apoptotic initiator,
BH3-only proteins, BAD, BID, BIK, BIM, BMF, bNIP3, HRK, Noxa, and PUMA) (Chipuk and
Green, 2008). The anti-apoptotic Bcl-2 proteins form heterodimers with BAK and BAX,
sequestering them and preventing activation of pro-apoptotic pathways. Apoptotic stimuli
induces BAK and BAX to form oligomers that insert themselves into the OMM, creating pores
(Chipuk and Green, 2008). These channels allow for the efflux of cytochrome c (cyt c) into the
cytosol. Under normal conditions, cyt c is anchored to the inner mitochondrial membrane via its
interaction with cardiolipin. It is thought that there are two pools of cyt c, either tightly and
loosely bound (Ott et al., 2002). Pore formation via BAK/BAX membrane insertion can trigger
the release of loosely bound cyt c, while the tightly bound pool requires cardiolipin oxidation for
dissociation and subsequent translocation to the cytosol (Ott et al., 2002; Orrenius and
Zhivotovsky, 2005). Upon occurrence of this event, cyt c forms an apoptosome complex with
procaspase-9 and apoptotic protease-activating factor 1 (Apaf-1) (Sas et al., 2007). The
apoptosome activates capsape-9, which subsequently activates procaspase-3 and/or procaspase-7,
leading to caspase-3/7 induced apoptosis (Sas et al., 2007).

The mitochondrial genome (mtDNA) sequestered within the mitochondrial matrix, encodes for
13 proteins of the ETC; the remaining 1500 mitochondrial proteins are nuclear encoded
(Taanman, 1999). Despite this, many of the genes encoded by mtDNA can be targeted by
miRNAs. For instance, miR-34a, has been shown to target NDUFC2 of complex I; SDHC of
complex II; UQCRB and QUCRQ of complex III, and COX10 of complex IV (Sarkar et al.,
2016). MiR-34a-mediated translational repression can prevent replacement of these proteins after
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normal turnover. If this were to occur, the ETC would not be able to function properly,
mitochondrial dysfunction would arise, and less ATP would be produced. Coincidently, we have
identified an NF-κB binding site on the promotor region of miR-34a (Sarkar et al., 2016),
suggesting that inflammatory stimuli which induce NF-κB activation also likely lead to the
upregulated transcription of miR-34a. In turn, this could perpetuate inflammation as
dysfunctional mitochondria contribute to increased ROS production and potential leakage of
mtDNA into the cytosol. Reduced mitochondrial function has also been implicated in many
neurodegenerative, neuroinflammatory diseases.

1.6 Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive, debilitating neurodegenerative disease which affects
nearly 6 million Americans, and is the 6th leading cause of death in the United States
(Alzheimer’s Association, 2016). The two hallmark lesions of the disease are intracellular
neurofibrillary tangles of hyperphosphorylated tau, and extracellular aggregation of amyloid beta
(Aβ) in the form of plaques, which are usually surrounded by dystrophic neurites and microglia.
The disease is also characterized by wide-spread cellular death, enlarged ventricles, and
significant reductions in cellular energy metabolism. At early stages of the disease, these
pathologies are first detected in the entorhinal cortex; as time and the disease progress, pathology
spreads into the temporal and frontal cortices, with much of the brain being affected at the later
stages (Braak and Braak, 1991a).

Axonal cytoskeletal proteins are stabilized by the microtubule-associated phosphoprotein, tau
(Binder et al., 1985; Buée et al., 2000; Kadavath et al., 2015). In AD and other tauopathies, tau
becomes hyperphosphorylated and dissociates from microtubules; the microtubules are no longer
stabilized and begin to break down, while the hyperphosphorylated tau begins to aggregate and
form intracellular tangles. Due to the breakdown of the microtubules, axonal transport of key
neurotrophic molecules necessary for neural signaling and survival is prevented, and cellular
death ensues. These dying cells release factors known as damage associated molecular patterns
(DAMPs), which can activate microglia for tissue clearance, and subsequently induce an immune
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response (Thundyil and Lim, 2015).

miRNAs have been shown to influence the expression and aggregation of tau. Both clinical
evidence and transgenic animal models indicate that anxiety is a common psychiatric symptom
experienced in AD (Teri et al., 1999; Blázquez et al., 2014), and it is likely due to tau
dysregulation (Pristerà et al., 2013). Anxiety may be the result of upregulated miR-92a in AD
brains; one target of this miR is vGAT, which is responsible for loading GABA, the main
inhibitory neurotransmitter, into secretory vesicles (Li et al., 2017). Dysregulation of GABA
signaling has been thought to contribute to anxiety, as neurons are left in an unregulated,
overexcited state. Both the overexpression of vGAT and the administration of a miR-92a
antagomir reduced anxiety-related behaviors in a mouse model of overexpressed human tau (Li
et al., 2017), suggesting a crucial role for miR-92a in the GABA secretory pathway, with
subsequent effects on anxiety behavior.

In the normal brain, amyloid precursor protein (APP) is constantly being cleaved (Selkoe, 1994;
Akiyama et al., 2000b), producing both soluble APPα (sAPPα) and sAPPβ (Nicolas and Hassan,
2014). Soluble APPα is non-pathogenic and does not accumulate, whereas sAPPβ can be
processed to Aβ 1-42 (Aβ42), and aggregate into fibrils and plaques, characteristic of AD
(Nicolas and Hassan, 2014). As extracellular Aβ42 accumulates and begins to form plaques, it
attracts and activates microglia (Falcão et al., 2017), which leads to the observation of a barrierlike ring of microglia around the plaque (Eikelenboom et al., 2006; Uslu et al., 2012; Hong et al.,
2016). Aβ resides in the center of the plaque, and other molecules, such as complement factors,
have also been observed within plaques (Eikelenboom et al., 1989). Complement-containing
plaques are capable of inducing full blown complement cascades within the AD brain
(Eikelenboom et al., 1989; Rogers et al., 1992; Fu et al., 2012), further contributing to chronic
local inflammation. Additionally, intracellular accumulations of Aβ42 have been observed within
microglia (Akiyama et al., 1996), as Aβ42 molecules can be phagocytosed by microglia prior to
aggregation in a dose- and time-dependent manner (Kopec and Carroll, 1998). In healthy brains,
this process occurs constantly (Ard et al., 1996), however in disease states, aggregated Aβ can be
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engulfed, but not easily broken down, as it can remain un-degraded within the microglia for
several days (Frackowiak et al., 1992).

AD is usually preceded by mild cognitive impairment. This condition is can be considered a
precursor to dementia, and is characterized by noticeable, but non-severe changes in memory. It
has been widely shown that adults diagnosed with MCI experience chronic brain vasculature
hypoperfusion, which can lead to increases in Aβ deposits and death receptor-6 (DR6) protein,
activation of caspases-3 and -6, and dendrite degeneration (Chen et al., 2017b). The presence of
DR6 has been implicated with neuronal loss and dendritic degeneration. miR-195 targets DR6
mRNA; upregulation of this miRNA has been demonstrated to reduce translation of DR6 protein,
and subsequently diminish the loss of both dendrites and neurons (Chen et al., 2017b). ADlinked neuronal loss and impaired neurite differentiation has also been linked to upregulation of
miR-211-5p; and these effects were found to be exacerbated in the presence of extracellular Aβ
(Fan et al., 2016). Longitudinal functional imaging studies also indicate that brain energy
metabolism is impaired in these patients, and longitudinal studies indicate that these reductions
in brain metabolism precede clinical onset of more severe symptoms characteristic of AD
(Fouquet et al., 2009; Mosconi et al., 2009; Sperling et al., 2010). As such, mitochondrial
dysfunction has been implicated in AD for decades (Castellani et al., 2002; Swerdlow and Khan,
2004). The mitochondrial cascade hypothesis posits that basal rates of mitochondrial function
and ROS production are determined by inherited functionality of the ETC. With time, some
individuals have a higher predisposition to greater accumulation of ROS-induced mtDNA
damage, which creates a positive feedback loop by increasing ROS generation even further by
increasing Aβ formation (Swerdlow and Khan, 2004). Indeed, from a molecular standpoint,
mitochondrial dysfunction leads to increases in APP processing towards the amyloidogenic
pathway (i.e. producing Aβ42) (Gabuzda et al., 1994; Atamna and Frey, 2007; Swerdlow et al.,
2014). Our laboratory has recently demonstrated that miR-34a is significantly upregulated within
the temporal cortex of post-mortem AD brains, as well as the temporal cortices and hippocampi
of a triple transgenic mouse model of AD (3xTgAD) (Sarkar et al., 2016). Additionally,
overexpression of miR-34a in primary neurons leads to subsequent mitochondrial dysfunction, as
indicated by reduced mitochondrial respiration and ATP production (Sarkar et al., 2016). As
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such, abhorrent upregulation of miR-34a may be a main contributor dysregulated energy
metabolism in the AD brain.

Unsurprisingly, many believe that in AD, neuroinflammation is a driving force behind
neurodegeneration (Akiyama et al., 2000b; Wyss-Coray, 2006). It is important to stress that
inflammation, in it of itself, is not a negative phenomenon. In addition to fighting off infections,
inflammatory responses are generated to remove and restore damaged tissue after injury. For
example, intrahippocampal injection of lipopolysaccharide (LPS) in amyloid precursor protein
(APP) transgenic mice triggers an inflammatory response, resulting in transient clearance of
diffuse amyloid-β (Aβ) deposits (Herber et al., 2004, 2007). Unfortunately, inflammation also
has the capacity to damage healthy surrounding tissue as well (Laskin and Pendino, 1995). As
such, chronic inflammation induced by the accumulation of extracellular Aβ plaques, DAMPs
released from dystrophic, necrotic cells, and accumulating mitochondrial ROS all appear to play
pertinent roles in the pathophysiology of AD. None of these factors alone have proven adequate
to explain the etiology of AD. The cause of this disease, and the driving force behind its
progression, appears to be very complex and may rely heavily on genetic risk factors and
regulatory mechanisms, which may easily implicate miRs in disease onset and progression.

1.7 Stroke
In recent years, the mortality rate of stroke has declined overall; however, it is still the 5th
leading cause of death and one of the most prominent causes of disability in the United States
(Yang et al., 2017). Every 40 seconds, someone in the United States experiences a stroke, and a
stroke-associated death occurs about every four minutes (Mozaffarian et al., 2016). While the
etiology of stroke is not fully understood, unhealthy lifestyle habits including poor diet, lack of
exercise, hypertension, and smoking all appear to contribute heavily to increased stroke risk
(Boehme et al., 2017).
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Strokes occur when a cerebral artery is blocked (ischemic stroke; 87% of cases) or ruptures
(intracerebral or subarachnoid hemorrhage; 10 and 3% of cases, respectively), resulting in a loss
of blood flow to the brain area supplied by that artery (Benjamin et al., 2017). Although proven
effective if administered to an eligible patient population, the therapeutic window of recombinant
tissue plasminogen activator (tPA), the most widely adopted thrombolytic agent, is exceptionally
short (3-4.5 hours from symptom onset), due to the increased risk of cerebral hemorrhage when
given after that time point.

During a stroke, brain tissue closest to the ischemic event is deprived of oxygen, glucose, and
other key nutrients and begins to die; this region is known as the ischemic core. The surrounding
tissue remains at-risk for death, and is commonly referred to as the penumbra. Necrotic cells in
the ischemic core release DAMPs which can activate microglia in the surrounding, penumbral
region. The activation of these cells can lead to further production of inflammatory mediators,
some of which can prompt further neuronal cell death, such as TNF-α and IL-1β (Zhang et al.,
2012). Post-stroke apoptosis occurs through activation of the intrinsic or extrinsic apoptosis
activation pathways. The intrinsic pathway activates mitochondrial mediated apoptosis, while the
extrinsic pathway initiates signaling of death receptor pathways (which may also activate
mitochondrial mediated apoptosis); both pathways result in the activation of caspase-3 and
subsequent initiation of apoptosis (Broughton et al., 2009). By reducing mitochondrial-mediated
apoptosis, Bcl-2 overexpression significantly reduces infarct volume in experimental stroke
models (Cao et al., 2002).

Microglial activation, and subsequent cytokine release, has been shown to be inhibited by
knockdown of miR-377 (Fan et al., 2017). In a rat MCAO stroke model, knocking down miR377 reduced ischemic infarct size by reducing inflammation mediated by microglial activation,
and promoting angiogenesis, thus leading to better stroke outcomes (Fan et al., 2017). As
inflammation-induced post-stroke upregulation of TNF-α occurs, there is a pronounced
downregulation of miR-181c in activated rat microglial cells; this relationship can be reversed by
transfecting microglia with miR-181c, thus decreasing levels of TNF- α, reducing inflammation,
and subsequently reducing neuronal cell death (Zhang et al., 2012). Indeed, genetically knocking
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out signaling components of the TNF-α death receptor pathway significantly reduced infarct
volume in experimental stroke models (Martin-Villalba et al., 1999).

Favorable stroke outcomes rely partially on the integrity of the BBB post-insult. As previously
discussed, the BBB can be compromised during periods of inflammation, and inflammation
induced via acute ischemic stroke is no different. Recent data implicate significant post-stroke
decreases of miR-122 in whole blood of both stroke patients and animal models (Liu et al.,
2016a). Targets of miR-122 include proteins that affect cell adhesion and leukocyte
extravasation. When miR-122 was administered into the blood, lower infarct volume and better
neurological outcomes were observed as compared to when it was directly injected into brain
ventricles, indicating that this miRNA is likely affecting CNS leukocyte invasion via peripheral
mechanisms rather than directly influencing CNS tissue (Liu et al., 2016a). In the stroke-prone
spontaneously hypertensive rat model, it was shown that prior to onset of stroke, levels of miR122 within the brain are decreased substantially. Additionally, vascular endothelial cells showed
heightened levels of inflammation and death, leading to degradation of the BBB, however these
responses were attenuated after exposure to miR-122 (Stanzione et al., 2017). Together, these
data suggest that miR-122 acts through the blood to improve the integrity of endothelial cells
comprising the BBB.

In the same vein, miR-126 and miR-126* also appear to regulate leukocyte adhesion and
infiltration across the BBB (Cerutti et al., 2017). These miRs are downregulated in response to
pro-inflammatory cytokines, such as TNF-α, which is upregulated post-stroke. When these
miRNAs are downregulated, VCAM1 and E-selectin levels are increased, respectively, and
leukocyte adhesion significantly increases (Cerutti et al., 2017), which can lead to enhanced
leukocyte extravasation into the brain, thus worsening patient outcomes. Additionally, miR-126
has been shown to facilitate vascular remodeling after cardiovascular insult, such as stroke. In a
mouse line with conditional endothelial cell knock-out of miR-126, knockout mice fared worse
than controls post-stroke, exhibiting higher levels of inflammation and cardiac hypertrophy
(Chen et al., 2017a). Stroke-induced miR-126 downregulation appears to play a large role in
outcomes related to inflammation and overall cardiovascular health after insult.
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The relationship between stroke and infection has also gained attention over the past several
decades, and recent infection is now considered a stroke risk factor (Grau et al., 1995, 2005;
Bova et al., 1996; Paganini-Hill et al., 2003). Systemic immune activation can significantly
contribute to thrombosis formation (Maurer et al., 2010), and thus increase the risk of
experiencing an ischemic stroke. Post-stroke infection is also a major cause of concern.
Immunosuppression is a common ailment seen in stroke patients (Cruse et al., 1992;
Członkowska et al., 1979; Meisel et al., 2005), and can commonly lead to development of
serious infections including pneumonia and urinary tract infections (Johnston et al., 1998;
Weimar et al., 2002). Lymphocyte counts are significantly reduced post-stroke, and those that
remain, exhibit a reduced ability to respond to inflammatory stimuli indicating that there is
reduced efficacy of the innate immune system signaling (Prass et al., 2003). As both stroke and
inflammation contribute to altering transcription of miRNAs, it is highly likely that these factors
work in a concerted fashion to mediate stroke onset and outcome severity.

1.8 Gaps in Knowledge
The above literature review introduces a broad range of topics, with an overarching focus on
neuroinflammation, and its associated diseases.

miRNAs
Pro-inflammatory stimuli like LPS and TNF-α are clearly implicated in the onset and progression
of neuroinflammation, however their effects on miRNA expression are a newer area of research.
Understanding the genetic nexus of neuroinflammation would provide new insights on
underlying disease pathology, mechanisms of progression, and more importantly, pathways and
targets for therapeutic intervention. As of 2015, over 2000 miRNAs had been identified
(Hammond, 2015), and it’s likely that this number is even larger now. As such, it is impossible
to study such a vast quantity of molecules with highly complex, network-level signaling effects.
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Our approach, as with many other groups, is to find a subset of miRNAs of interest, and explore
their role in various disease states. In this regard, we focus on the miRNAs, miR-34a and -146a.
We have previously demonstrated that in the AD brain, they are significantly upregulated in a
disease-stage specific manner. Understanding how this relates to the pathophysiology of disease
progression will shed light on how inflammatory stimuli influence their expression, as well as
the functional consequences of this. AD progression is characterized by chronic
neuroinflammation and reduced brain energy metabolism, and potential targets of miR-34a and 146a include several proteins involved in cellular bioenergetics. Understanding how these
miRNAs fit into the broader picture of inflammation and mitochondrial dysfunction could
provide insight on the potential benefits of utilizing these miRNAs as therapeutic targets in
disease.

Neuronal EVs
As inflammation has been shown to affect the biogenesis and secretion of EVs as well, it comes
as no surprise that the study of EVs in the context of neuroinflammation is also gaining traction.
Much of the work in this field however, focuses more so on EVs derived from glial cells.
Functional studies regarding neuronal uptake of EVs is also within the context of glial cellderived EVs. Many groups focusing on neuronal-derived EVs are interested in the clinical and
diagnostic aspects of these vesicles, via the identification and development of assays for
identifying neuronal-derived EVs in circulating biological fluids (e.g. plasma, CSF) (Saman et
al., 2012; Mustapic et al., 2017; Sun et al., 2017). Many other studies focusing on neuronal
derived EVs concentrate on the effects of synaptic activity on EV production, and their role in
cell-to-cell communication (Wang et al., 2017b; Xu et al., 2017; Polanco et al., 2018). There are,
however, some groups whom do focus on the effects inflammation or injury-induced neuronal
EVs (Putz et al., 2008; Simeoli et al., 2017). To our knowledge, no other groups have assessed
the bioenergetic outcomes of neuronal uptake of inflammation-induced neuronal-derived EVs.

Intermittent LPS Exposure
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Interactions between the systemic immune and central nervous systems are highly complex.
Stroke risk factors are associated with unhealthy lifestyle habits, which may increase systemic
inflammation. Others have demonstrated that LPS exposure, when administered between 1 and 7
days of experimental stroke, is neuroprotective and leads to smaller infarct volumes (Rosenzweig
et al., 2004, 2007; Stevens et al., 2008). In line with this proposed timeframe, we previously
demonstrated that exposure to lipopolysaccharide (LPS) 30 minutes prior to experimental stroke
significantly increases stroke infarct volume (Doll et al., 2015b). Evidence examining repeated
LPS exposure appears limited to repeated dosing over several consecutive days prior to stroke
(Rosenzweig et al., 2007), however this paradigm is not clinically relevant. To model more
closely the rate of sickness experienced in humans, we were interested in determining the effects
of intermittent LPS exposure, from which animals recover, and the impact this may have on
stroke outcomes.
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2.1 Abstract
Alzheimer’s disease (AD) and other neurodegenerative diseases are characterized by chronic
neuroinflammation and a reduction in brain energy metabolism. An important role has emerged
for small, non-coding RNA molecules known as microRNAs (miRNAs) in the pathophysiology
of many neurodegenerative disorders. As epigenetic regulators, miRNAs possess the capacity to
regulate and fine tune protein production by inhibiting translation. Several miRNAs, which
include miR-146a, are elevated in the brain, CSF, and plasma of AD patients. miR-146a
participates in pathways that regulate immune activation and has several mRNA targets which
encode for proteins involved in cellular energy metabolism. An additional role for extracellular
vesicles (EVs) has also emerged in the progression AD, as EVs can transfer functionally active
proteins and RNAs from diseased to healthy cells. In the current study, we exposed various cell
types present within the CNS to immunomodulatory molecules and observed significant
upregulation of miR-146a expression, both within cells and within their secreted EVs. Further,
we assessed the effects of miR-146a overexpression on bioenergetic function in primary rat glial
cells and found significant reductions in oxidative phosphorylation and glycolysis. Lastly, we
correlated miR-146a expression levels within various regions of the AD brain to disease staging
and found significant, positive correlations. These novel results demonstrate that the modulation
of miR-146a in response to neuroinflammatory stimuli may mediate the loss of mitochondrial
integrity and function in cells, thereby contributing to the progression of beta-amyloid and tau
pathology in the AD brain.
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2.2 Introduction
Many neurodegenerative diseases, including Alzheimer’s disease (AD), are characterized by
chronic neuroinflammation. Prolonged, unregulated inflammation leads to the increased
production of various pro-inflammatory molecules, which likely contribute to disease
progression. Although the genetics of late-onset Alzheimer’s disease are complex, recent studies
have observed significant downregulation of many genes necessary for proper cellular
bioenergetics (Liang et al., 2008). Moreover, functional imaging studies of patients suffering
from AD reveal that the severity of brain hypometabolism is correlated with dementia (Brier et
al., 2012; Yin et al., 2016). It is clear that dysfunctional brain energetics is an important aspect of
AD pathology, yet the molecular mechanisms responsible are poorly understood.

Due to their ability to regulate translational repression of multiple mRNA targets, microRNAs
(miRNAs) have recently been implicated as major players in the pathogenesis of AD. A
deleterious, pro-inflammatory role has emerged for miR-146a in AD (Alexandrov et al., 2014),
as well as other neurological (Nguyen et al., 2018) and degenerative diseases (Pogue and Lukiw,
2018). Classically, miR-146a has been considered a well-characterized anti-inflammatory
miRNA, as several mRNA targets include genes that encode for interleukin 1 receptor associated
kinase (IRAK1), TNFR-associated factor 6 (TRAF6), and signal transducer and activator of
transcription 1 (STAT1) (Taganov et al., 2006; Cui et al., 2010; Iyer et al., 2012; Wang et al.,
2013). Many of these proteins work as transcription factors to increase production of
inflammatory cytokines or induce apoptosis; therefore miR-146a mediated translationalrepression of these signaling molecules can reduce inflammatory responses within cells. In
contrast, more recent studies also suggest a pro-inflammatory role for miR-146a function and
have observed increased expression of miR-146a in response to oxidative stress and
inflammation (Lukiw and Alexandrov, 2012; Wu et al., 2015; Cardoso et al., 2016). Elevated
levels of miR-146a have also been shown to downregulate expression of complement factor H
(CFH), an important repressor of inflammation (Lukiw et al., 2008). Thus, a growing body of
literature strongly suggests that miR-146a participates in both pro- and anti-inflammatory roles
in human health and disease.
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In addition to the physical hallmarks of AD such as extracellular Aβ plaques, intracellular
neurofibrillary tangles, and neuronal loss, widespread hypometabolism is also observed within
the AD brain (de Leon et al., 2001; Mosconi et al., 2006, 2008). Interestingly, several mRNAs
encoding for proteins involved in cellular metabolism have recently been identified as targets of
miR-146a; these proteins have been demonstrated to play important roles in glycolysis,
mitochondrial respiration, mitochondrial transport, and apoptosis (Rippo et al., 2014). Due to its
inflammation-induced upregulation, and the mRNAs in which it targets, miR-146a may be a key
player in the pathophysiology and progression of AD.

How miR-146a-mediated inflammatory signals accelerate or exacerbate AD progression is
unclear. It is well-established that AD typically progresses in a very characteristic manner with
initial pathology developing in the entorhinal cortex, then spreading throughout the temporal
cortex, and finally into the frontal cortex (Smith, 2002). Propagation of disease pathology from
one cell to another may be due, in part, to communication between cells via extracellular vesicles
(EVs). EVs are small, nano-sized particles shed or excreted from most cell types, which have the
capacity to transfer functional RNAs, including miRNAs, from one cell to another (Valadi et al.,
2007; van Niel et al., 2018). Thus, EVs have been implicated in the spread of pathological
molecules during disease states that include AD and other neurodegenerative diseases (reviewed
by Thompson et al., 2016).

Previous work from our laboratory and others, have shown that miR-146a is significantly
upregulated in the brains of AD patients, compared to their age-matched controls (AMCs)
(Sarkar et al., 2016; Pogue and Lukiw, 2018). In the current study, we assessed the effects of
various inflammatory mediators on different cell types within the CNS, the functional
bioenergetic outcomes of miR-146a overexpression, and the relationship between human brain
miR-146a expression and AD pathology. We hypothesized that miR-146a expression would
increase after exposure to inflammatory stimuli, and that overexpression of this miRNA would
lead to decreased cellular bioenergetics. Further, we hypothesized that AD brains would have
significantly higher levels of miR-146a expression when compared to age matched controls
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(AMCs), and these levels would positively correlate with disease severity, and negatively
correlate with total mitochondrial protein expression.

2.3 Experimental Procedures
Animals
Pregnant rats (Sprague Dawley) were acquired from Hilltop Laboratory (Scottdale, PA) to obtain
E18 brain tissue for preparation of mixed glial and cortical neuronal cultures. Three timedpregnant female rats were used for each primary culture experiment, with 6-10 embryos per dam,
and each experiment was repeated three times. Therefore, nine timed pregnant female rats were
used for all animal experiments. All animal studies were approved by the Institutional Animal
Care and Use Committee at West Virginia University.

Cell culture
Primary culture: Pregnant rats were euthanized and fetal brain tissue was harvested from E18
rats. Brains were removed and placed into magnesium (Mg2+) free Hank's balanced salt solution
(HBSS). Cortices and hippocampi were removed under a dissecting microscope, washed, and
placed into neurobasal culture media (without phenol red) supplemented with 1X B27 and 1%
penicillin-streptomycin (Gibco, Carlsbad, CA). The cortices and hippocampi were triturated
using a graded series of fine polished Pasteur pipettes, and then filtered through a 40 μm nylon
cell strainer (Becton Dickinson Labware, Franklin Lakes, NJ). Neurons were plated on poly-Llysine coated 150-mm dishes and cultured in vitro in 95% humidity and 5% CO2 atmosphere at
37°C for 15 days. At day 2, cells were exposed to 5 μM 1-β-D- arabinofuranosyl cytosine (AraC)
to inhibit glial cell growth as previously described (Sarkar et al., 2015, 2016). To obtain glial
cells, following trituration the remaining cortical and hippocampal cell suspension was grown in
DMEM for 4-5 days until a mixed glial population of astrocytes and microglia reached
confluency.

Immortalized cell lines: A hippocampal neuronal cell line, HT-22 cells, was obtained from Dr.
David Schubert at the Salk institute. Additionally, a cerebellar microglial cell line, C8-B4 cells,
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and a brain microvascular endothelial cell line, bEnd.3 cells, were both obtained from ATCC
(Manassas, VA). All cell lines were of murine origin and grown in Dulbecco’s Modified
Essential Medium (high glucose) (Hyclone) with 10% FBS 1% pen/strep in humidified 95%
air/5% CO2 at 37ºC.

Human brain tissues
Brain tissue from the temporal cortex, frontal cortex, and cerebellum of confirmed AD patients
and AMCs was obtained from the Kathleen Price Bryan Brain Bank, Bryan Alzheimer’s Disease
Research Center, Duke University Medical Center, Durham, NC. All tissues were staged for AD
pathology with Braak and Braak staging (Braak and Braak, 1991b) and cerebral amyloid
angiopathy (CAA) (Thal et al., 2003). Brain tissues were used in accordance with the
institutional review board/ethical guidelines of the donor institution.
Preparation of soluble amyloid-beta (A)
Synthetic Aβ1–42 (Tocris, Ellisville, MO) oligomers were prepared without the fibrillar
component according to published methods (Barghorn et al., 2005; Sarkar et al., 2015). Briefly,
Aβ1–42 was dissolved in 1,1,1,3,3,3- hexafluoro-2-propanol to 1 mM. The clear solution was
then evaporated to dryness. Dried peptide was diluted in DMSO to 5 mM and sonicated for 10
min in a bath sonicator. The peptide solution was resuspended in cold Neurobasal medium and
immediately vortexed. The solution was then incubated at 4°C for 24 h. After high speed
centrifugation, the supernatant was collected, visualized by polyacrylamide gel electrophoresis
and silver staining, and found to be comprised of fibrillar-free oligomers and monomers.

Extracellular vesicle isolation
HT-22 cells were seeded in 100 mm dishes and exposed to 1 ng/ml tumor necrosis factor-alpha
(TNF-α) when cells reached 80% confluency. C8-B4 and bEnd.3 cells were seeded in 150 mm
dishes, and when cells reached 50% confluency, they were exposed to either 1 μg/ml LPS
(Sigma-Aldrich, St. Louis, MO) or 1 ng/ml TNF- (R&D, Minneapolis, MN). Similarly, rat
cortical primary neuronal and glial cells were grown in 150 mm dishes and when cells were 75%
confluent, they were exposed to 250 or 500nM of oligomeric A. For all cell types and exposure
34

conditions, after 24 hours, the media was collected for EV isolation and downstream miRNA
purification. EVs were isolated from the cell culture media by either ultracentrifugation (Théry et
al., 2006; Sarkar et al., 2015) or ExoRNeasy Isolation Kit (Qiagen, Germantown, MD) according
to the manufacturer’s protocol. Using the ultracentrifugation method, the conditioned cell culture
media was centrifuged (320 x g for 5 minutes) to remove cells, and the supernatant was filtered
through a Steriflip filter (0.22 µm pore size). EVs were pelleted from the filtered media by
ultracentrifugation at 100,000 g for 60 min at 4°C using Beckman SW 28 rotor running in a
Beckman Coulter Optima L-100 XP ultracentrifuge (Beckman Coulter, Brea, CA). EVs were
washed once with sterile PBS, collected by ultracentrifugation, and resuspended in 1 ml of sterile
PBS.

Overexpression of miR-146a in primary mixed glial cells
To induce overexpression of miR-146a in cells and their secreted EVs, rat primary mixed glial
cells were transfected with either vector or miR-146a expression plasmid DNA by Lipofectamine
2000 (Invitrogen, Carlsbad, CA). The miR-146a expression vector was purchased through
Addgene (Addgene plasmid #15092, Cambridge, MA), which was deposited from David
Baltimore (Taganov et al., 2006). Forty hours after transfection, EVs in the conditioned media
were prepared as described above. The presence or absence of miR-146a was determined by
isolating total RNA using the miRNeasy Kit (Qiagen) followed by qRT-PCR as described below.

miRNA expression analysis
Total RNA enriched in miRNAs was isolated from approximately 5 mg of individual frozen
brain tissue samples and various cell samples by using the miRNeasy Micro Kit Isolation Kit
(Qiagen). Total RNA enriched in miRNAs was also isolated from EVs using the miRNeasy
Serum/Plasma Kit. Prior to isolation of EV RNA, 3.5 µl C. elegans miR-39 (at a concentration of
1.6 x 108 copies/μl) was added to each sample as a spike-in control. Total RNA concentrations
were measured using a Nanodrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA).
Using the miScript II RT Kit (Qiagen), 2µg of total RNA containing miRNA was reverse
transcribed in a total volume of 10µl reaction mix to make cDNA. Expression of miR-146a was
determined by quantitative RT-PCR, which was performed using target specific miScript primer
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assays and the miScript SYBR® Green PCR Kit (Qiagen). All reactions were performed in
triplicate for each sample using a StepOne Plus PCR system (Applied Biosystems, Foster City,
CA) for 40 cycles as follows: 10 sec at 95 °C, 30 sec at 55°C, 30 sec at 70 °C. Negative control
reactions were included as wells containing only master mix and nuclease-free water without any
template cDNA. All miRNA specific primers were from Qiagen and included: miScript Primer
Assay Hs_miR-146a (MS00003535), Hs_RNU6 (MS00033740), and Ce_miR-39_1 (219610).
The expression levels of miR-146a were standardized against those of RNU6 (an internal control
for brain tissue and cell samples) and miR-39 (a spike-in control for EV samples) detected in
identical cDNA samples. Quantification of PCR amplified miRNA specific cDNA was done by
the comparative cycle threshold CT method (∆∆CT) (Livak and Schmittgen, 2001).

Measurement of mitochondrial respiration: oxygen consumption rate (OCR)
Approximately 20,000 primary mixed glial cells per well were seeded in a XFe 96 cell culture
microplate (Agilent, Santa Clara, CA) in DMEM medium with 10% FBS and 1% pen/strep. The
next day, glial cells were transfected with either vector or miR-146a expression plasmid DNA (1,
2, 3, or 4 µg/ml) by Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol.
Forty hours after transfection, OCR was measured by the XFe 96 Extracellular Flux Analyzer
using a Mito Stress Kit (Agilent) according to the manufacturer’s protocol. To measure
mitochondrial function in real time, oligomycin, carbonyl cyanide p-[trifluoromethoxy]-phenylhydrazone (FCCP), and antimycin A plus rotenone were added separately to a sensor cartridge
and injected sequentially through ports in the XF Assay cartridge to final concentrations of 1
µg/ml, 1 µM and 10 µM, respectively. Addition of these reagents allowed for measurement and
calculation of the basal level of mitochondrial oxygen consumption, the amount of oxygen
consumption linked to ATP production, the level of non-ATP-linked oxygen consumption
(proton leak), the maximal respiratory capacity, and the non-mitochondrial oxygen consumption.
For each experimental condition six replicate wells were used.

Measurement of glycolytic function: extracellular acidification rate (ECAR)
Similarly, as performed for OCR, primary mixed glial cells were cultured in a XFe96 cell culture
microplate and transfected with vector or miR-146a expression plasmid DNA. Forty hours after
36

transfection, ECAR was measured by XFe 96 Extracellular Flux Analyzer using a Glycolysis
Stress Kit (Agilent) which measures three key parameters of glycolytic function: glycolysis,
glycolytic capacity, and glycolytic reserve. A saturating concentration of glucose, oligomycin,
and 2-deoxy-glucose (2-DG; a glucose analog) were added separately in a sensor cartridge and
injected sequentially through ports in the cartridge to final concentrations of 10 mM, 0.6

M,

125mM, respectively. This assay allows for the calculation of the basal rate of
glycolysis/glycolytic flux, maximum glycolytic capacity, and glycolytic reserve. For each
experimental condition, six replicate wells were used.

Western blot analysis
To prepare total protein extracts, frozen human brain tissues were homogenized in in Pierce®
RIPA buffer (Thermo Scientific) with 100x HaltTM Protease Inhibitor Single-Use Cocktail
(Thermo Scientific), followed by centrifugation at 13,400 g for 5 min at room temperature. The
supernatant was collected and the protein concentrations were determined using PierceTM BCA
Protein Assay (Thermo Scientific). Approximately 15 g total protein was separated by size in
Bolt 4-12% Bis-Tris Plus poly-acrylamide gels (Novex®, Thermo Scientific) through
electrophoresis, along with the ChameleonTM Kit Pre-stained Protein Ladder (LI-COR, Lincoln,
NE) size marker. Proteins were transferred to iBlot® 2 PVDF membranes (Invitrogen, Thermo
Scientific) by iBlot® 2 Gel Transfer Device (Life Technologies). The membranes were blocked
in Odyssey blocking buffer in TBS (LI-COR) for 1 hour at room temperature, and then incubated
with primary antibodies of target proteins in sequential manner overnight at 4°C: VDAC
(MilliporeSigma, Burlington, MA, (MABN504), 1:1,000 dilution), and β-actin (Adipogen (YIFLF-PA0209) 1:15,000 dilution). The following day, membranes were washed with 1x TBST
buffer (prepared with 1x Tris buffered saline with 0.1% Tween 20) 3 times for 5 minutes, and
incubated with appropriate anti-rabbit, anti-mouse, secondary antibody conjugated with
fluorescence dye (LI-COR, IRDye 800CW anti-Rabbit and anti-Mouse, both 1:15000 diluted in
blocking buffer) for one hour, then washed again in 1x TBST 3 times in 5 minute intervals prior
to imaging. The specific reaction was visualized by using the Odyssey CLx (LI-COR), and
immunoblotting bands were quantified by densitometry using Image Studio 5.1.
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Statistical analyses
All experiments were repeated at least 3 times with n=3-6 wells/treatment/experiment. Results
from the experiments are reported as means ± SEM. Quantitative results that satisfied criteria for
parametric analyses were assessed for significance using Welch’s t-test for two sample
comparisons or a one-way ANOVA with Tukey’s post hoc test for three or more comparisons.
Data in Figures 3 and 4 were analyzed using regression models where miRNA is the independent
variable and ATP production, maximal respiration, protein leak, and spare capacity were
dependent variables; all models showed a significant negative linear trend. Spearman’s  was
calculated to determine correlations between miR-146a levels and Braak or CAA staging.
Specific details of the statistical reporting for each experiment are provided in the corresponding
figure legend. All analyses were performed using R 3.5.1 (https://wwww.R-project.org) and
GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA). A p value ≤ 0.05 was used to establish
significance; significance presented as *p≤0.05, **p≤0.01, and ***p≤0.0001.

2.4 Results
Neuroinflammatory stimuli induce upregulation of miR-146a in several CNS cell types and their
EVs
Due to the heterogeneity of cell types within the CNS, our first goal was to understand how
diverse inflammatory stimuli influence miR-146a production in various cells and their released
EVs. To this end, we utilized an immortalized neuronal cell line (HT-22), a microglial cell line
(C8-B4), and a brain endothelial cell line (bEnd.3). Cells were exposed to either TNF-α (1
ng/ml), a proinflammatory cytokine which is upregulated in AD (Decourt et al., 2016), or
lipopolysaccharide (LPS) (1 μg/ml), which may be released from bacteria in the gastrointestinal
tract and cross the aged BBB (Zhao and Lukiw, 2018), for 24 hours. TNF-α exposure of HT-22
cells significantly increased miR-146a expression both intracellularly (Fig 1A) and in secreted
EVs (Fig 1D). Levels of miR-146a in C8-B4 cells were also significantly increased in response
to LPS exposure both intracellularly (Fig 1B) and in secreted EVs (Fig 1E). A similar pattern of
miR-146a expression was also examined in bEnd.3 cells (Fig 1C) and EVs (Fig 1F) exposed to
LPS, however TNF-α exposure appears to affect these cells in a different manner. Although
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exposure to this cytokine induced significant upregulation of miR-146a in bEnd.3-derived EVs
(Fig 1F), intracellular expression of miR-146a is significantly reduced. These data suggest the
possibility of cell-type specific, as well as stimulus specific regulatory mechanisms, which
influence miRNA packaging and secretion in EVs.
A exposure induces upregulation of miR-146a in primary neurons and mixed glial cells and
their EVs
To determine if neuroinflammation-induced alterations in miR-146a were species specific, we
next used rat primary neurons and primary mixed glial cells. For 24 hours, these cells were
exposed to A; a neuroinflammatory component of plaques and one of the hallmarks of AD. We
observed a significant upregulation of miR-146a expression in primary neurons (Fig 2A), and a
dose-dependent increase in their secreted EVs (Fig 2C). Exposure of primary mixed glia to A
induced similar responses, with a dose-dependent increase of miR-146a expression
intracellularly (Fig 2B), and a significant upregulation within their secreted EVs (Fig 2D).

miR-146a inhibits oxidative phosphorylation and glycolysis in primary mixed glial cells
Previous work has shown that miR-146a targets several mRNAs which encode for proteins of the
mitochondrial electron transport chain (Rippo et al., 2014) and glycolysis (Raschzok et al.,
2011). Hence, we hypothesized that elevated levels of miR-146a would lead to significant
impairment of cellular bioenergetics. To test this, we overexpressed miR-146a in rat primary
mixed glial cells and measured oxidative phosphorylation and glycolysis using the Mito Stress
Kit or Glycolysis Stress Test Kit (Agilent Biosciences). To ensure transfection efficiency prior to
use of either of the metabolic stress kits, rat primary mixed glial cells were transfected with
either vehicle vector or miR-146a overexpression vector, and cultured for 40 hours. We then
assessed miR-146a expression levels intracellularly and in secreted EVs qRT-PCR. As shown in
Table 1 when compared to vehicle vector, transfection of the miR-146a overexpression vector
increased intracellular miR-146a levels more than 2-fold, while EV levels were increased in a
dose-dependent manner (53 to 116-fold). In addition, we assessed cellular viability 40 hours after
transfection with a calcein AM assay and observed no effects on cellular viability (data not
shown).
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We next examined the effects of miR-146a overexpression on oxidative phosphorylation. After
40 hours of transfection, we observed a dose-dependent decrease in all OCR parameters
assessed, including ATP production (Fig 3A), spare capacity (Fig 3B), maximal respiration (Fig
3C), and proton leak (Fig 3D) when compared to vector transfected cells. In addition, ECAR
values were also measured 40 hours after transfection. Similarly, we observed a dose-dependent
decrease in glycolysis (Fig 4A), glycolytic capacity (Fig 4B), and glycolytic reserve (Fig 4C)
when compared to vector transfected cells. These data suggest that miR-146a has the capacity to
alter cellular bioenergetics by impairing both mitochondrial function and glycolysis.

miR-146a expression is positively correlated with pathological scores in human AD brains
Several groups have demonstrated that miR-146a levels are significantly increased in neocortical
brain regions of AD patients, along with multiple biological fluids including serum, plasma, and
cerebrospinal fluid (Alexandrov et al., 2012; Lukiw et al., 2012; Denk et al., 2015; Dong et al.,
2015; Kumar and Reddy, 2016). To test if miR-146a expression exhibits a brain region specific
phenotype, we analyzed miR-146a levels from the temporal cortex (TC), frontal cortex (FC), and
cerebellum (CB) of 10 control and 13 AD patient brains. In accordance with previous reports by
Lukiw et al. (2012), we confirmed that miR-146a levels are significantly increased in the TC of
AD patients (3.6-fold) when compared to AMCs (Fig 5A). We also observed increased levels of
miR-146a in the FC (5.3-fold; Fig 5D) and CB (3.7-fold; Fig 5G), but this trend did not reach
statistical significance due to high variation among samples.

To test if the variation was due to the severity of AD pathology, we further analyzed miR-146a
levels in brains when stratified by Braak stage (3 and 6). The increase of miR-146a in AD brains
is most highly correlated with Braak stage 6, which designates late stage AD, regardless of
which brain region we assessed; 5.7-fold in TC (Fig 5B), 8.6-fold in FC (Fig 5E), and 6.8-fold in
CB (Fig 5H). We observed a significant positive correlation between increased levels of miR146a and the severity of Braak staging of AD patients for all three of the assessed brain regions
(Figs 5C, 5F, and 5I). Further correlational analyses also indicated that levels of miR-146a were
positively correlated with CAA. These data suggest that both tau pathology (as assessed with
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Braak staging) and amyloid burden on cerebral vasculature (as assessed with CAA) are
correlated with increased levels of miR-146a.

Due to our finding that overexpression of miR-146a in primary mixed glial cells significantly
reduces cellular bioenergetics, and miR-146a expression is significantly elevated in AD brains,
we next probed for changes in total mitochondrial protein (VDAC1) levels within the temporal
cortices of AD and AMC brains (Fig 6A). We found a significant negative correlation between
increased expression levels of miR-146a and decreased mitochondrial protein (Fig 6B).
Together, our findings suggest that as AD progresses, expression of miR-146a increases and is
correlated with decreased expression of mitochondrial protein.

2.5 Discussion
In the current study, we have described a novel role for miR-146a in the pathophysiology of AD.
We demonstrated that various inflammatory stimuli induce upregulation of miR-146a in several
cell types of both mouse and rat origins. Our assessment of the functional impacts of elevated
levels of miR-146a on cellular bioenergetics reveal novel and very interesting findings which
indicate that further mechanistic probing is warranted. In addition to our in vitro studies, we
utilized human brain samples to demonstrate that patients suffering from AD express
significantly elevated levels of miR-146a when compared to AMCs. From these data, we
propose that miR-146a plays a key role in the progression and pathophysiology of AD.

During periods of neuroinflammation, microglia and astrocytes act as the first responders and
initiate an immune response (Dong and Benveniste, 2001; Yang et al., 2010). This response can
be beneficial in the short term, as invading pathogens or aberrantly expressed molecules are
cleared to protect and preserve neuronal function (Sochocka et al., 2017a). The negative
consequences of neuroinflammation arise when the inflammatory response becomes prolonged,
or chronic, such as the case for patients suffering from AD (Sochocka et al., 2017b). As AD
progresses, the cells of the CNS are exposed to many inflammatory stimuli, including cytokines,
chemokines, and A aggregates (Akiyama et al., 2000a). Here, we have shown that with
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prolonged exposure to these immunomodulatory molecules, miR-146a expression is significantly
increased. In line with our results, other recent studies have also shown that miR-146a expression
occurs within cells of the CNS, including choroid plexus epithelium (Balusu et al., 2016), human
neural cells (Lukiw et al., 2008), and brain endothelial cells (Wu et al., 2015). Similar to our
findings, another group recently showed that exposure of glial cells to A activates nuclear
factor kappa-B (NF-κB) and induces miR-146a expression (Denk et al., 2015). Interestingly,
inflammation-induced miR-146a expression has been reported in various other tissues/cell types,
including immune cells (macrophage, dendritic, neutrophil, T cells and B cells) (Taganov et al.,
2006; Lu et al., 2010; Boldin et al., 2011; Sun et al., 2015), hepatocytes (Sun et al., 2015),
cardiomyocytes, bronchial epithelial cells, endothelial cells (HUVEC), orbital adipose tissue, as
well as mesenchymal stem cells (Fu et al., 2017; Song et al., 2017). Together, these findings
support the notion that inflammatory stimuli induces upregulation of miR-146a in a wide variety
of cell types, and that this mechanism is likely involved in the immune response.

In addition to intracellular increases of miR-146a, we also found significant increases in miR146a expression in the EVs secreted from cells exposed to various inflammatory stimuli. EVmediated spread of disease may exacerbate the neuroinflammatory response (Rajendran et al.,
2006) due to their ability to transfer functionally active proteins and RNAs to recipient cells
(Ratajczak et al., 2006; Valadi et al., 2007). As inflammation-induced EVs are taken up by
neighboring cells, their contents can be transferred into recipient cells and exert functional
effects (i.e. miRNAs contained within EVs can repress protein translation in recipient cells)
(Valadi et al., 2007). We observed a substantial upregulation of miR-146a in isolated EVs
induced from exposure neuroinflammatory stimuli at levels much greater than control, and
conclude that this is indicative of an increase in EVs derived from cultured cells. Taken together,
our results are in agreement with others (Alexander et al., 2015; Song et al., 2017), and support
the concept that EVs play a role in disease progression due to their ability to transfer aberrant
proteins and RNAs to recipient cells.

In the AD brain, A plaque deposition is considered a pathological hallmark of the disease and
has been shown to induce inflammation. Previous work has observed the accumulation of Aβ
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aggregates within microglia, as these brain immune cells attempt to degrade the insoluble protein
aggregates to no avail (Paresce et al., 1997; Lee and Landreth, 2010; Krabbe et al., 2013; Baik et
al., 2016). Additionally, complement factors and other inflammatory molecules have been
observed within plaques themselves (Eikelenboom et al., 1989). It is clear that while the brain is
trying to rid itself of these extracellular aggregates, an inflammatory response is being initiated
within the surrounding tissue. Evidence from in vitro studies has shown that in response to A
exposure, cultured human neuronal and glial cells upregulate expression of miR-146a due to the
activation of NF-κB (Lukiw et al., 2008; Cui et al., 2010). Increased expression of miR-146a has
been associated with another major characteristic of AD, tau hyperphosphorylation, via the
repression of rho-associated, coiled-coil containing protein kinase 1 (ROCK1) (Wang et al.,
2016).

To better understand the interplay between inflammatory stimuli and decreased cellular
bioenergetics, we investigated the potential effects of elevated levels of miR-146a on
mitochondrial function and glycolysis. We show for the first time, that overexpression of miR146a leads to profound reductions in several parameters of mitochondrial function and glycolytic
capabilities of primary mixed glial cells, which supports the notion that miR-146a exerts proinflammatory effects when it is significantly upregulated. Although we have not tested the direct
effects of inflammatory stimuli on cellular bioenergetics, previous work has demonstrated that
exposure to pro-inflammatory cytokines such as TNF-α and IL-1β leads to alterations in glucose
metabolism and oxidative stress in astrocytes (Gavillet et al., 2008). In addition to classical
inflammatory mediators, chronic exposure to soluble Aβ peptides also results in impairment of
energy homeostasis due to the decreased respiratory capacity of the mitochondrial electron
transport chain; this may accelerate neuronal death (Rhein et al., 2009) as neurons are extremely
dependent on aerobic metabolism and oxygen use. Despite a large reservoir of ATP, neurons are
heavily dependent on aerobic metabolism and oxygen use, so reductions in ATP availability due
to impaired glycolytic and/or mitochondrial function results in neuronal cell death (Goldberg and
Choi, 1993; Lee et al., 2012b).
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Lukiw (2007) first demonstrated differential miRNA expression patterns in AD hippocampi, and
later Cogswell et al. (2008) observed this phenomenon in specific brain regions and
cerebrospinal fluid (CSF). Another group also found that miR-146a expression levels were
significantly upregulated in both the CSF and hippocampi of AD patients (Denk et al., 2015). In
addition to measuring miR-146a expression, we also correlated levels within specific brain
regions (frontal and temporal cortices, and cerebellum) to Braak & Braak staging (Braak and
Braak, 1991b), and found significant positive correlations between these two factors.
Additionally, expression levels of miR-146a were also positively correlated with CAA, which is
characterized by deposition of Aβ in the media and adventitia of cortical and leptomeningeal
vessels (Salvarani et al., 2016). Aging and AD are established risk factors for developing CAA
(Yamada, 2015), suggesting that not only parenchymal deposition of Aβ, but also intravascular
accumulation, affects the expression of miR-146a during disease progression. These data
indicate that multiple cell types may mediate the increase in miR-146a levels in AD and other
neurological disease states. Brain hypometabolism is also significantly correlated with increased
dementia in AD (Liang et al., 2008). Here, we have shown that within the temporal cortex of AD
patients, as miR-146a expression increases, total mitochondrial protein decreases. Together these
data support the hypothesis that inflammation-induced miR-146a overexpression contributes to
brain hypometabolism in AD.

In summary, we have shown that inflammatory stimuli expressed within the AD brain induce
upregulation of miR-146a in a variety of cell types. Parallel findings in multiple brain cell types
(neurons, astrocytes, microglia, and endothelial cells) and species (mouse, rat, and human)
demonstrate that our observations may represent a common CNS inflammatory response
mediated, in part, by miR-146a. Our functional data indicate that the overexpression of miR146a significantly impairs cellular bioenergetic function and may lead to the hypometabolic
phenotype seen in clinical AD. These results suggest a novel pro-inflammatory mechanism of
action for miR-146a in the neuroinflammatory etiology of AD and related dementias.
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Table 2.1: Fold change in miR-146a levels following transfection in primary mixed glial
cells
Forty hours after transfection of vehicle or overexpression vector, total RNA was purified from
primary mixed glial cells and their isolated EVs and miR-146a expression levels were assessed.
All data were expressed as mean  SEM ;* p<0.05 compared to vector control.

miR-146a expression (relative fold change)
Transfection

Intracellular

Extracellular Vesicle

Vector 4 μg/ml

1.0  0.2

1.0  0.0

miR-146a 2 μg/ml

2.1  0.1

53  19

miR-146a 4 μg/ml

2.3  0.4

116  20 *
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Figure legends
Figure 2.1: Effects of pro-inflammatory stimuli on intracellular and EV miR-146a levels in
different brain cell types. (A & D) Murine hippocampal neurons (HT-22 cells), (B & E) brain
microglia (C8-B4 cells), or (C & F) brain endothelial cells (bEnd.3) were exposed to either LPS
(1 μg/ml) or TNF- 1 ng/ml for 24 hours, followed by purification of cellular and EV miRNA.
Intracellular miR-146a expression was greater in TNF-α exposed neurons (A) than in untreated,
control cells (t8.1 = -2.63, p≤0.05.) Similarly, TNF-α exposure also significantly increased miR146a expression in secreted neuronal EVs (D) when compared to EVs secreted from unexposed,
control cells (t7.1 = 7.06, p ≤ 0.0001.) Intracellular miR-146a expression was not significantly
altered in microglial cells after exposure to LPS (B) when compared to unexposed, control cells
(t2.1 = -8.39, p = 0.10.) Interestingly however, microglial EVs contained significantly elevated
levels of miR-146a after exposure to LPS (E) when compared to unexposed control cells (t4 =
53.58, p ≤ 0.0001). Intracellular miR-146a expression levels in brain endothelial cells exposed
to LPS were significantly elevated when compared to control, while TNF-α exposure lead to
significantly reduced miR-146a expression (C) (F2,6 = 135.6, p ≤ 0.0001). EVs secreted from
brain endothelial cells had significantly elevated miR-146a expression after LPS or TNF-α
exposure, when compared to EVs secreted from unexposed, control cells (F) (F2,6 = 383.7, p ≤
0.0001). Data are presented as means  SEM with significance as *p≤0.05, **p≤0.01,
***p≤0.001.

Figure 2.2: Effects of A on intracellular and EV miR-146a levels in primary neurons and mixed
glial cells. (A & C) Rat primary neurons and (B & D) mixed glial cells were exposed to 0, 250,
and 500 nM of A for 24 hours, followed by purification of cellular and EV miRNA. Primary
neurons exposed to both concentrations of Aβ expressed significantly higher levels of
intracellular miR-146a (A) when compared to unexposed, control cells (F2,6 = 21.94, p ≤ 0.01).
Similarly, EVs secreted from primary neurons exposed to both concentrations of Aβ expressed
significantly higher levels of miR-146a (C) when compared to EVs secreted from unexposed,
control cells (F2,6 = 147.4, p ≤ 0.0001). Primary microglia exposed to both concentrations of Aβ
expressed significantly higher levels of intracellular miR-146a (B) when compared to unexposed,
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control cells (F2,6 = 90.70, p ≤ 0.0001). Lastly, EVs secreted from primary microglia exposed to
both concentrations of Aβ expressed significantly higher levels of miR-146a (D) when compared
to EVs secreted from unexposed, control cells (F2,6 = 34.65, p ≤ 0.01). Data are presented as
means  SEM with significance as *p≤0.05, **p≤0.01, ***p≤0.001.

Figure 2.3: Functional effects of ectopically expressed miR-146a on oxidative phosphorylation in
rat primary mixed glial cells. Mixed primary glial cells were transfected with a miR-146a
overexpression vector for 40 hours, and mitochondrial function was assessed. ATP production
(A) was significantly reduced in a miR-146a dose-dependent fashion (F1,71 = 120, p ≤ 0.0001).
Spare respiratory capacity (B) was significantly reduced in a dose-dependent fashion (F1,72 =
120.6, p ≤ 0.0001). Maximal respiration was significantly reduced in a dose-dependent fashion
(F1,72 = 199.8, p ≤ 0.0001). Proton leak was significantly reduced in a dose-dependent fashion
(F1,70 = 77.66, p ≤ 0.0001). Data were analyzed by using regression models that showed a
negative linear trend between the independent variable (miR-146a) and each dependent variable.
All data are presented as means  SEM.

Figure 2.4: Overexpression of miR-146a reduces glycolysis in rat primary mixed glia.
Rat primary mixed glia were transfected with a miR-146a overexpression vector and 40 hours
after transfection, glycolysis was assessed. All data were analyzed using an ANOVA linear
contrast. Glycolytic capacity (A) was significantly reduced in a miR-146a dose-dependent
manner (F1,73 = 85.23, p ≤ 0.0001). Glycolysis (B) was significantly reduced in a dose-dependent
fashion (F1,74 = 150.7, p ≤ 0.0001). Glycolytic reserve (C) was significantly reduced in a dosedependent manner (F1,71 = 32.25, p ≤ 0.0001). Data were analyzed by using regression models
that showed a negative linear trend between the independent variable (miR-146a) and each
dependent variable. All data are presented as means  SEM.

Figure 2.5: miR-146a profile and correlation with pathology in human Alzheimer's disease (AD)
regions compared to age-matched controls (AMC): temporal cortex (TC), frontal cortex (FC) and
cerebellum (CB). Relative fold change of miR-146a levels in AD cases (n=13) compared with
AMCs (n=10) shows significant increases in the TC (A; t11.2 = 2.54, p ≤ 0.05) and FC (D; t12.2 =
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2.29, p ≤ 0.05) of AD brains when compared to AMCs. Of the AD brains, seven AD cases were
diagnosed as Braak & Braak (B&B) stage VI, and six were diagnosed as stage III. The
relationship of miRNA expression with B&B stage (control, 0 vs. 3 vs. 6) was also assessed to
determine B&B stage specific miR-146a expression in human brains and found significant
increases within the TC (B; F2,19 = 9.91, p ≤ 0.01), FC (E; F2,20 = 7.05, p ≤ 0.01) and CB (H; F2,21
= 7.19, p ≤ 0.01). Correlation of miR-146a expression with B&B stage or amyloid angiopathy
(AA) was calculated by using Spearman’s rho () and showed a significant correlation of miR146a with B&B stage: (C) TC, =0.68, p≤ 0.001; (F) FC, =0.61, p≤ 0.01; (I) CB, =0.56, p≤
0.01 and AA: (C) TC, =0.53, p≤ 0.05; (F) FC, =0.48, p≤ 0.05; (I) CB, =0.49, p≤ 0.05). Data
are presented as means  SEM with significance as *p≤0.05, **p≤0.01, ***p≤0.001.

Figure 2.6: Mitochondrial protein levels are inversely correlated with miR146a gene expression.
(A) Western blot of representative AD and AMC temporal cortex shows levels of the
mitochondrial protein, voltage-dependent anion channel (VDAC, 35 kD), and the cytosolic
housekeeping protein, -actin (46 kD). (B) VDAC levels were normalized to beta-actin for each
sample (VDAC/-actin). The correlation between the VDAC/-actin ratio and miR-146a
expression revealed an inverse releationship between total mitochondrial proteins and miR146a
expression (Spearman’s  = -0.80, p≤0.01).
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consumption in recipient cells. Frontiers in Neuroscience. In
press.
3.1 Abstract
Extracellular vesicles (EVs) are small, membrane-bound nanoparticles released from most, if not
all cells, and can carry functionally active cargo (proteins, nucleic acids) which can be taken up
by neighboring cells and mediate physiologically relevant effects. In this capacity, EVs are being
regarded as novel cell-to-cell communicators, which may play important roles in the progression
of neurodegenerative diseases, like Alzheimer’s disease. Aside from the canonical physical
hallmarks of this disease (amyloid β plaques, neurofibrillary tangles, and widespread cell death),
AD is characterized by chronic neuroinflammation and mitochondrial dysfunction. In the current
study, we sought to better understand the role of tumor necrosis factor-alpha (TNF-α), known to
be involved in inflammation, in mediating alterations in mitochondrial function and EV
secretion. Using an immortalized hippocampal cell line, we observed significant reductions in
several parameters of mitochondrial oxygen consumption after a 24-hour exposure period to
TNF-α. In addition, after TNF-α exposure we also observed significant upregulation of two
miRNAs (miR-34a and miR-146a) associated with mitochondrial dysfunction in secreted EVs.
Despite this, when naïve cells are exposed to EVs isolated from TNF-α treated cells,
mitochondrial respiration, proton leak, and reactive oxygen species (ROS) production are all
significantly increased. Collectively these data indicate that a potent proinflammatory cytokine,
TNF-α, induces significant mitochondrial dysfunction in a neuronal cell type, in part via the
secretion of EVs, which significantly alter mitochondrial activity in recipient cells.
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3.2 Introduction
Alzheimer’s disease (AD) is a chronic neurodegenerative disease characterized by amyloid β
(Aβ) plaques, neurofibrillary tangles, neuroinflammation, and mitochondrial dysfunction (WyssCoray and Rogers, 2012). Extracellular Aβ plaques activate microglia, prompting secretion of
immunomodulatory molecules, including tumor necrosis factor-alpha (TNF-α) (Hanisch, 2002).
Elevated levels of this cytokine have been detected in the plasma (Fillit et al., 1991; Zuliani et
al., 2007), cerebrospinal fluid (CSF) (Tarkowski et al., 2003), and brains (Sharma et al., 2012) of
AD patients when compared to healthy, age matched controls (AMCs). Further, several studies
have implicated TNF-α as a key player in the formation of amyloid β (Aβ) plaques (Blasko et al.,
2000; Liao et al., 2004; Yamamoto et al., 2007), suggesting that this cytokine may participate in
a vicious cycle of AD progression. TNF-α activates the transcription factor NF-κB (Schütze et
al., 1995), which induces the transcription of many genes, including microRNAs (miRNAs);
these small, non-coding RNAs function as gene repressors by base-pairing with complementary
mRNAs and inhibiting protein translation, or accelerating the de-adenylation of the poly-A tail
(Krek et al., 2005; Huntzinger and Izaurralde, 2011). Changes in expression of various miRNAs
have been associated with inflammation and may influence AD progression.

Previous work from our laboratory assessed brain region-specific changes in miRNA expression,
and observed significant upregulation of miR-34a and miR-146a in AD patients’ temporal
cortices, when compared to AMCs (Sarkar et al., 2016). Promotor analysis revealed that various
components of the NF-κB family bind to the promotor region of both miR-34a (Sarkar et al.,
2016) and miR-146a (Taganov et al., 2006), suggesting that the activation of pro-inflammatory
pathways could lead to increased transcription of these miRNAs. Interestingly, these miRNAs
target several mRNAs, which encode for proteins of the mitochondrial electron transport chain
(ETC) (Dasgupta et al., 2015; Sarkar et al., 2016). Indeed, overexpression of miR-146a in
primary microglial cells (Jun et al., unpublished observation) or miR-34a in primary neurons
(Sarkar et al., 2016) significantly reduced mitochondrial function, and repressed expression of all
of the associated mitochondrial proteins that were assessed (Sarkar et al., 2016). Inflammationinduced upregulation of NF-κB may lead to aberrant expression of miR-34a and -146a and lead
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to translational repression of ETC proteins, thus contributing to the widespread reductions in
glucose metabolism and dysregulated mitochondrial function observed in AD brains.

Intercellular communication allows for the transfer of information from one cell to another. The
secretion of extracellular vesicles (EVs) affords the opportunity for cells to send important
signaling molecules out into the extracellular environment to convey vital messages to
neighboring cells (Harding et al., 1983; Pan et al., 1985; Valadi et al., 2007; Tkach and Théry,
2016). As EVs are encapsulated by a lipid bilayer, their contents (including proteins, DNA, and
RNA) are protected from degrading enzymes, allowing for delivery of functional cargo. During
periods of neuroinflammation, concentrations of circulating EVs have been shown to be
significantly upregulated, and within the context of AD, EVs have been shown to confer noxious
molecules, including Aβ (Rajendran et al., 2006; Sardar Sinha et al., 2018), to recipient cells and
thereby participate in the spreading of AD pathology and neuroinflammation.

Inasmuch as neuroinflammation clearly occurs in affected individuals, and likely occurs years
prior to onset of clinical symptoms, it is difficult to model in vitro, the effects of long-term
inflammation. In the current study, we sought to characterize the role of acute TNF-α exposure
on phenotypes seen in AD, including mitochondrial dysfunction, increased miRNA expression
(e.g. miR-34a and miR-146a) (Sarkar et al., 2016), and altered EV secretion in an immortalized
hippocampal cell line (HT-22). Here we demonstrate that direct exposure to TNF-α for 24-hours
significantly reduces mitochondrial oxygen consumption, induces cellular death, and induces
differential expression of miR-34a and miR-146a both within cells, and in secreted EVs. We also
assessed the functional outcomes of exposing TNF-α naïve cells to TNF-α-induced EVs and
found significant increases in mitochondrial oxygen consumption, proton leak, and reactive
oxygen species (ROS) production.

3.3 Materials and Methods

Cell culture
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The HT-22 immortalized mouse hippocampal cells were obtained from the Salk Institute for
Biological Research (La Jolla, CA, USA). HT-22 cells were cultured in Hyclone Dulbecco’s
modified Eagle’s medium (DMEM)/high glucose (Fisher Scientific, Waltham, MA, USA) with
10% fetal bovine serum (FBS) (Atlanta Biologicals, Flowery Branch, GA, USA) and 1%
penicillin/streptomycin (Fisher Scientific). When cells were at least 80% confluent, they were
trypsinized and spun down at 325.5 x g for 3 minutes. Cells were counted with a Nexcelom
Bioscience Cellometer AutoT4 (Lawrence, MA, USA). Cell passages 5-18 were used for all
experiments.

Cytokine reconstitution and exposure
Recombinant mouse TNF-α was purchased from R&D Systems (Minneapolis, MN, USA) and
reconstituted at 100 μg/ml in phosphate-buffered saline (PBS) containing 0.1% bovine serum
albumin. Dilutions were made in Hyclone DMEM/high glucose with 10% exosome-depleted
FBS (Fisher Scientific), and 1% penicillin/streptomycin to obtain concentrations of 0.1, 1, and 10
ng/ml. The 24-hour time point for TNF-α exposure was chosen as preliminary data suggested
that shorter exposure period did not result in mitochondrial dysfunction (data not shown). Longer
exposure periods were not tested due to the potential complication of TNF-α-induced
neurotoxicity on cell number, which could affect readouts of all of the assessed parameters in
this study.

EV isolation from cell culture media
Conditioned media was collected after a 24-hour exposure to TNF-α and filtered through a
Millex-AA Syringe Filter Unit, 0.80 μm (Millipore Sigma, Burlington, MA, USA) to remove
cellular debris. EV isolation was performed as per the manufacturer’s instructions using either
the ExoRNeasy Serum Plasma Maxi Kit (Qiagen, Germantown, MD) utilized for RNA
purification from EVs, or the ExoEasy Maxi Kit (Qiagen) for all other EV applications.

Briefly, 1 volume of filtered media was mixed with 1 volume of buffer XBP and then placed on
a spin column and centrifuged at 500 x g for 1 minute. The flow-through was discarded and the
column was washed with 10 ml buffer XWP and centrifuged at > 3000 x g for 5 minutes. The
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column was then transferred to a new collection tube and the EVs were eluted with 700 μl
QIAzol for downstream RNA purification, or 400 μl buffer XE for all other EV applications.

Particle size distributions and concentrations
To determine if changes in EV concentrations after exposure to TNF-α could account for
alterations in mitochondrial function, EVs were isolated from HT-22 cell conditioned media
using the ExoEasy Maxi Kit (as described above) and profiled with the NanoSight NS300
(Malvern, Westborough MA, USA). In the final isolation step using the ExoEasy Maxi Kit, EVs
were eluted from the spin column membrane in 400 μl XE Buffer. Suspended EVs were diluted
1:200 in sterile filtered PBS for injection into the NanoSignt NS300 unit. Capture and analysis
settings were manually set according to the manufacturer’s instructions. Particles were visualized
using laser light scattering to quantify nanoparticles (10-1000 nm) moving under Brownian
motion as they pass through the flow chamber. The Nanoparticle Tracking Analysis (NTA)
software generates particle size distributions and concentrations based on an analysis of both
Brownian motion and light scattering observed from tracked particles.

EV marker dot blot
The presence of several EV markers was assessed to ensure that isolated particles from control or
TNF-α exposure groups were indeed EVs. Protein concentration was measured using a
microBCA kit (Fisher). BSA standards were prepared in the same solution EVs were eluted in
(XE Buffer). EVs were diluted in 2% sodium dodecyl sulfide (SDS) at a ratio of 1:10 to a final
volume of 150 μl, and transferred to a 96 well clear bottom assay plate. The standard curve was
prepared using 150 μl of each, in duplicate. Working reagent was prepared in a 25: 24: 1 ratio of
reagents A, B, and C, respectfully. 150 μl working reagent was added to each of the standards
and diluted EV samples, and incubated at room temperature for 2 hours on a shaker. The plate
was read using a BioTek Synergy H1 Hybrid reader at 562 nm absorbance.

The Exo-Check Exosome Antibody Array (System Biosciences) was used to detect the presence
of several EV markers as per the manufacturer’s instructions. Briefly, from either control or
TNF-α induced EVs, 200 μg protein was incubated with 600 μl Exosome Lysis buffer and
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vortexed. Next, the lysate mixture was combined with 9.4 mL Exosome Array Binding buffer
and was then added to a pre-wet antibody array membrane and incubated overnight at 4°C on a
shaker. The following day the membrane was washed and 10 mL Detection buffer was added to
the membrane and incubated for 2 hours on a shaker. Next, the membrane was washed 3x and 2
mL SuperSignal West Femto Chemi-luminescent Substrate (Fisher) developer solution was
added and the membrane was imaged.

Mitochondrial functional assessment
HT-22 cells were seeded at 5k per well in an XFe96 cell culture microplate (Agilent, Santa Clara,
CA) for 24 hours. Media was gently aspirated from the cells and replaced with 100 μl Hyclone
DMEM/high glucose, supplemented with 10% exosome-depleted FBS and 1%
penicillin/streptomycin, the various concentrations of TNF-α, or isolated TNF-α-induced EVs.
For EV exposure, EVs were isolated from the media of HT-22 cells exposed to varying
concentrations of TNF-α (0, 0.1, 1, and 10 ng/ml) for 24 hours. As described above, EVs were
isolated from 20 ml media of cytokine-exposed HT-22 cells and eluted from spin columns in 400
μl buffer XE. Assuming a high yield of recovery from a starting volume of 20 ml conditioned
cell culture media, EVs eluted in 400 μl buffer XE would be concentrated 50x. To mimic in vitro
EV concentrations from each cytokine exposure condition, EVs were diluted 50x in DMEM/high
glucose, supplemented with 10% exosome-depleted FBS and 1% penicillin/streptomycin (i.e. 2
μl EVs suspended in buffer XE were diluted into 98 μl media per well). Various parameters of
mitochondrial function were assessed using a Mito Stress kit, with the XFe96 Analyzer. Using
Wave 2.4.0 Desktop software, all mitochondrial assessments were calculated with the Agilent
Seahorse XF Cell Mito Stress Test Report Generator. Non-mitochondrial oxygen consumption
rate (OCR) was calculated as the minimum rate measurement after rotenone/antimycin A
injection. Basal respiration was calculated by subtracting non-mitochondrial OCR from the last
rate measurement before oligomycin injection. Maximal respiration was calculated by
subtracting non-mitochondrial OCR from the maximum rate measurement after
trifluorocarbonylcyanide phenylhydrazone (FCCP) injection. Proton leak was calculated by
subtracting non-mitochondrial OCR from the minimum rate measurement after Oligomycin
injection. ATP production was calculated by subtracting the minimum rate measurement after
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Oligomycin injection from the last rate measurement before Oligomycin injection. Lastly, spare
respiratory capacity was calculating by subtracting basal respiration from maximal respiration.
All measurements are displayed percent changes from control. All wells with a basal respiratory
rate below 40 pmol/min were excluded from analysis.

While glycolysis was not directly measured, data on the extracellular acidification rate (ECAR)
is an additional measurement collected while completing the Mito Stress test. From these
measurements, basal levels of glycolytic activity can be determined. To determine basal
glycolysis, the third measurement, prior to the injection of oligomycin, was used. For cells
treated with TNF-α, the average ECAR reading was calculated, and was used to calculate percent
of control for each of the TNF-α treatment groups (0, 0.1, 1, and 10 ng/ml). For cells treated with
EVs derived from TNF-α exposed cells, the cells treated with the XE buffer served as the
control, and percent of control was calculated in the same way in each of the treatment groups (0,
0.1, 1, and 10 ng/ml).

Lactate dehydrogenase assay
Cell death after cytokine or EV exposure was assessed using the Pierce™ lactate dehydrogenase
(LDH) Cytotoxicity Assay (Fisher Scientific) kit. Reaction substrates were prepared as per the
manufacturer’s instructions. LDH assay was performed with the media from the XFe96 cell
culture microplate. Forty-five minutes prior to the end of the 24-hour exposure period, 10 μl 10x
lysis buffer was added to one control well, and the plate was placed back in the incubator. At the
conclusion of the exposure period, 50 μl of media was carefully removed from each well and
transferred to a new 96 well clear bottom assay plate. The well exposed to 10x lysis buffer was
excluded from the mitochondrial functional assessment. Next, 50 μl of the LDH reaction mixture
was added to each well, and the plate was incubated for 30 minutes at room temperature,
protected from light. The reaction was stopped by adding 50 μl of LDH stop solution to each
sample. The plate was read using the BioTek Synergy H1 Hybrid reader (BioTek, Winooski,
VT) at absorbance of 490 nm and 680 nm. Cell death was calculated as a percentage of total
death, relative to maximal cell death induced by treatment with the 10x lysis buffer.
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Intracellular and EV miRNA analysis
Cells were seeded at 250k per 10 cm cell culture dish and left to reach ~80% confluency over the
course of 48 hours. Media was gently aspirated from cells, and replaced by 10 ml of Hyclone
DMEM/high glucose, supplemented with 10% exosome-depleted FBS and 1%
penicillin/streptomycin, or the various concentrations of TNF-α. After a 24 hour exposure period
the media was collected for EV isolation, and cell lysates were collected using a Cell Lifter
(Corning, Corning, NY, USA), washed with PBS, and pelleted by centrifugation at 325.5 x g for
3 minutes, followed by the addition of 700 μl QIAzol Lysis Reagent for RNA purification
(Qiagen).
RNA was purified from EVs eluted in 700 μl QIAzol by using the exoRNeasy Serum Plasma
Maxi Kit (Qiagen). For all EV samples, 3.5 μl miRNeasy Serum/Plasma Spike-In Control (C.
elegans miR-39; at a concentration of 1.6 x 108 copies/μl) was added to each sample, followed
by the addition of 90 μl chloroform and a 3 minute incubation. Next the samples were
centrifuged for 15 minutes at 12,000 x g at 4°C. The upper aqueous phase (300 μl) was
transferred to a new collection tube and mixed with 600 μl 100% ethanol. The solution was then
placed on an RNeasy MinElute spin column and centrifuged at 12,000 x g for 15 seconds. The
flow through was discarded and 700 μl buffer RWT was added to the spin column and
centrifuged at 12,000 x g for 15 seconds. Two washes of 500 μl buffer RPE were then
performed, the first lasting 15 seconds and the second lasting 2 minutes. The RNeasy MinElute
spin column was then placed in a new collection tube and spun at 12,000 x g for 5 minutes to dry
the column membrane. Lastly, the column was placed in another collection tube and 28 μl
RNase-free water was added to the center of the membrane and incubated for 1 minute, and then
centrifuged at 12,000 x g for 1 minute ending with the purified RNA eluted in the collection
tube. Cellular RNA was purified using the miRNeasy Mini Kit (Qiagen) as per the
manufacturer’s instructions, similar to the purification process for EVs, as described above.

RNA concentrations for each sample were measured using Nano drop 2000 spectrophotometer
(Thermo Scientific). For cDNA synthesis, 0.75 μg total RNA containing microRNAs was
reverse transcribed using the miScript II RT kit (Qiagen). A 10 μl total volume reaction mix was
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made using 2 μl 5x miScript HiSpec Buffer, 1 μl 10x miScript Nucleics Mix, 1 μl miScript
Reverse Transcriptase Mix, and 6 μl Template RNA/nuclease-free water. Prior to use for qRTPCR, cDNA was diluted in nuclease-free water, at a ratio of 1:10.

Previous work from our laboratory indicates that of a panel of miRNAs assessed, only miR-34a
and miR-146a showed disease-stage related increases in expression in both human AD and triple
transgenic AD mouse (3xTgAD) brains. Therefore, expression of miR-34a and miR-146a were
profiled for both EV and intracellular levels using target specific miScript primer assays and the
miScript SYBR® Green PCR kit (Qiagen) (5 μl SYBR® Green; 1 μl Universal Primer; 1 μl
Target Primer; 3 μl diluted cDNA). Quantitative RT-PCR reactions were performed in triplicate
for each sample, using the CFX384 Touch™ Real-Time PCR Detection System (Bio-Rad,
Hercules, CA, USA) for 45 cycles as follows: 15 sec at 94 °C, 30 sec at 55 °C, 30 sec at 70 °C.
Negative control reactions were included as wells containing only master mix and nuclease-free
water (no template cDNA). All miRNA specific primers were miScript Primer Assays (Qiagen);
Hs_RNU6-2_11 (MS00033740), Ce_miR-39_1 (219610), Hs_miR-34a (MS00003318), and
Hs_miR-146a (MS00003535). The expression levels of target genes in EVs were standardized
against those of the spike-in control, c.elegans miR-39 gene, detected in identical cDNA
samples, while the expression levels of target genes in cell lysates was standardized against
RNU6. Quantification of PCR amplified microRNA specific cDNA was done by comparative
cycle threshold CT method (2-ΔΔCT).

EV uptake via naïve cells
To determine if naïve HT-22 cells have the capacity to take up cytokine-induced EVs, cells were
incubated with EVs labeled with Exo-Red Exosome RNA Fluorescent Label (System
Biosciences, Palo Alto, CA). EVs isolated from all TNF-α exposure groups were labeled as per
the manufacturer’s protocol. Briefly, ~100 μg protein of isolated EVs were incubated with 50 μl
Exo-Red for 10 minutes at 37°C. ExoQuick-TC reagent (100 μl) was then added to the labeled
EV suspension and mixed by gentle inversion. This solution was incubated on ice for 30
minutes, followed by centrifugation at 14,000 rpm for 3 minutes. The supernatant was removed
and the EV pellet was resuspended in 500 μl PBS. Next, 100 μl labeled EVs were added to naïve
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HT-22 cells in a 6-well dish (~80% confluent), and imaged with the Nikon Swept Field Confocal
microscope (Nikon, Melville, NY) approximately 10 minutes after addition to naïve cells.

Mitochondrial membrane potential assay
Mitochondrial membrane potential (Ψm) was measured using the tetramethylrhodamine, ethyl
ester (TMRE) (Abcam, Cambridge, United Kingdom) reagent. Cells were grown in a 96 well
clear bottom black plate and exposed to TNF-α induced vesicles as described for the Seahorse
assay. At the end of the experiment, media was gently aspirated from the wells and replaced by
100 μl of 60 nM TMRE in cell culture media, and incubated at 37°C for 20 minutes, protected
from light. Cells were gently washed three times with warmed HBSS and fluorescence was
measured on a Synergy HT multimodal plate reader with excitation 549 nm and emission 575
nm.

Mitochondrial superoxide assay
The levels of mitochondrial superoxide in cells were determined using the MitoSOXTM reagent
(Fisher). Cells were grown in a 96 well clear bottom black plate and exposed to TNF-α induced
vesicles as described for the Seahorse assay. At the end of the experiment, media was gently
aspirated from the wells and replaced by 100 μl of 5 μm MitoSox in cell culture media and
incubated for 10 minutes at 37°C, protected from light. Cells were gently washed three times
with warmed HBSS and fluorescence was measured on a Synergy HT multimodal plate reader
with excitation 510 nm and emission 580 nm.

Hydrogen peroxide assay
The hydrogen peroxide assay was performed using the Amplex Red Kit (Invitrogen). Cells were
grown in a 96 well clear bottom black plate, and exposed to TNF-α induced vesicles as described
for the Seahorse assay. At the end of the experiment, 50

L of the Amplex Red reagent was

added to the media in the plate without washing, and incubated for 30 min at room temperature.
The fluorescence of the Amplex Red reagent was measured on a Synergy HT multimodal plate
reader with excitation 530 nm and emission 590 nm.
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Statistical analyses
All biological experiments were repeated at least 3 times with n=3-16 plates/wells per treatment.
Results from the experiments are reported as means ± SEM. All quantitative data were assessed
for significance using a one-way ANOVA with Dunnett’s post hoc test. All results were
analyzed by GraphPad Prism 8.0 software (GraphPad Software, La Jolla, CA). A p value < 0.05
was used to establish significance; significance presented as *p<0.05, **p<0.01, ***p<0.001,
and ****p<0.0001.

3.4 Results
TNF-α induces mitochondrial dysfunction and cellular death
A Seahorse mitochondrial stress test was conducted to assess mitochondrial function in HT-22
cells exposed to TNF-α for 24 hours. Results indicate that TNF-α exposure reduced basal and
maximal respiration, ATP production, and spare capacity in a dose-dependent manner, with
significant reductions occurring at the two highest concentrations (1 and 10 ng/ml) compared to
unexposed control cells (Figures 1A-D). These same concentrations of TNF-α induced
significant proton leak (Figure 1E), which can reduce the Ψm, and uncouple oxidative
phosphorylation (Terada, 1990; Jastroch et al., 2010). Significant, dose-dependent decreases in
basal glycolysis were also detected as a result of TNF-α exposure (Figure 1F). Exposure to all
concentrations of TNF-α lead to cell death as shown by significant increases in lactate
dehydrogenase (LDH) present in the conditioned culture media (Figure 1G). In view of the
apparent cell death induced by increasing doses of TNF-α (Figure 1G), the observed decline in
oxidative phosphorylation (Figures 1A-D) and glycolysis (Figure 1F) may be caused by the loss
of cells in the assay.
TNF-α exposure induces EV secretion, but not in a dose-dependent fashion
We next assessed the ability of TNF-α exposure to induce EV secretion in this hippocampal cell
line. Vesicles isolated from the conditioned media of TNF-α exposed cells were profiled using
the NanoSight NS300. Interestingly, TNF-α exposure lead to increased EV particle number,
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however this effect does not appear to be dose-dependent (Figures 2A, B). Exposure to low (0.1
ng/ml) and high (10 ng/ml) concentrations of TNF-α significantly increased particle
concentration, whereas exposure to 1 ng/ml TNF-α did not lead to particle concentrations above
control. Additionally, TNF-α exposure did not alter vesicle size, as all EV size distributions were
between ~80-300 nm in diameter, consistent with what has been shown in the literature (van Niel
et al., 2018).

As recommended by the International Society for Extracellular Vesicles (Lötvall et al., 2014), we
probed for the presence of several canonical EV markers, including ALIX, CD81, CD63, and
TSG101. Vesicles isolated from both the control and TNF-α exposure groups expressed all of the
expected markers (Figure 2C) indicating that EVs were indeed being isolated in the vesicle
preparation.
TNF-α alters miRNA expression intracellularly and in secreted EVs
In order to determine the impact of acute TNF-α exposure on miRNA expression, we assayed
miR-34a and miR-146a expression within cells and their secreted EVs 24-hours after exposure.
Interestingly, intracellular expression levels of miR-34a were not changed after exposure to
TNF-α (Figure 3A), yet a dose-dependent significant upregulation of this miRNA was observed
in the secreted EVs (Figure 3B). Intracellular miR-146a expression was significantly increased
after TNF-α exposure with an apparent ceiling effect (Figure 3C), and was significantly
increased in a dose-dependent fashion in secreted EVs (Figure 3D).

EVs are taken up by, and enhance mitochondrial function in recipient cells
Because the secreted EVs contained TNF-α dose-dependent increased expression of both miR34a and miR-146a, we were interested in determining whether EV cargo could be delivered to
TNF-α naïve recipient cells, and how this may affect their mitochondrial function. We exposed
TNF-α naïve cells to EVs isolated from the media of TNF-α exposed cells whose RNA was
fluorescently labeled; EVs delivered this RNA to naïve recipient cells (Figure 4). We then
assessed mitochondrial function, using the XFe96 Mito Stress kit, in EV-recipient cells at 24
hours after exposure. To our surprise, we observed significant, dose-dependent increases in
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mitochondrial oxygen consumption after EV exposure (Figures 5A-D). Interestingly, we also
observed significant increases in proton leak (Figure 5E) suggesting that although oxidative
phosphorylation is increased, mitochondria are likely not functioning optimally, as protons are
leaking across the membrane. We also observed a significant dose-dependent upregulation of
basal glycolysis after exposure to EVs (Figure 5F). Unlike direct exposure to TNF-α, only EVs
induced from the highest concentration of TNF-α (10 ng/ml) caused significant cell death in
naïve cells (Figure 5G). The enhanced oxidative phosphorylation (Figures 5A-D) and glycolysis
(Figure 5F) seen after exposure to TNF-α-induced EVs is likely an underestimate of the
bioenergetic function of the cells exposed to 10 ng/ml TNF-α-induced EVs, as this group
experienced significant cell death (Figure 5G).

EVs increase ROS production in recipient cells
Due to the increased proton leak observed in the Seahorse assay following EV exposure, we next
assessed mitochondrial Ψm. We did not observe any significant changes in potential (Figure 6A)
after a 24 hour exposure period to TNF-α induced EVs.
We next assessed ROS production in cells exposed to TNF-α induced EVs. We observed a
statistically significant increase in mitochondrial superoxide production when cells were
incubated with EVs induced by 0, 0.1, and 1 ng/ml TNF-α, but not 10 ng/ml (Figure 6B);
however this result may be attributed to the significant amount of cell death observed in this
group (Figure 5G). Additionally, we observed significant increases in hydrogen peroxide (H2O2)
after exposure to EVs, with the highest amount generated in the 10 ng/ml TNF-α induced EV
group (Figure 6C). As H2O2 has the capacity to induce neuronal cell death (Ricart and Fiszman,
2001), this may explain why we observed significant cellular death in this group (Figure 5G).

3.5 Discussion
AD is characterized by neuroinflammation (Wyss-Coray and Rogers, 2012) and mitochondrial
dysfunction (Swerdlow, 2018). In the present study, we observed that physiologically relevant
levels of the proinflammatory cytokine TNF-α are capable of causing significant cellular death
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and mitochondrial dysfunction in hippocampal neurons after a 24-hour exposure period. We also
demonstrate that TNF-α induced EVs are taken up by naïve cells, and significantly alter
mitochondrial activity in recipient cells. Specifically, we observed increases in mitochondrial
respiration, glycolysis, proton leak, and ROS production in recipient cells after 24 hours of EV
exposure. Together, these data suggest that direct exposure of TNF-α to a neuronal cell type is
highly toxic, and the vesicles secreted in response to this exposure are capable of inducing a
stress response in neighboring cells.

We observed significant downregulation of mitochondrial oxidative phosphorylation and
glycolysis in HT-22 cells exposed to TNF-α for 24 hours. Under some conditions, when
oxidative phosphorylation is inhibited or reduced, neurons can increase glycolysis as a
protective, compensatory mechanism (Bas-Orth et al., 2017). However, with the decline in
oxidative phosphorylation observed in this study, there is no compensatory increase in
glycolysis. We additionally assessed expression of several electron transport chain proteins
involved in oxidative phosphorylation (including NDUFC2 of complex I, SHDC of complex II,
UQCRB of complex III, and Cytochrome C oxidase of complex IV) after TNF-α exposure, and
observed no significant changes in expression (data not shown). High concentrations of LDH in
the media, along with reductions in bioenergetic measurements indicate that these observations
are likely a result of cell death due to exposure to the cytotoxic protein, TNF-α.

We have previously shown that overexpression of miR-34a significantly reduces mitochondrial
function in neuronal cells (Sarkar et al., 2016). In view of our evidence that miR-146a, but not
miR-34a, was increased intracellularly in HT-22 cells, miR-146a may be responsible for the
TNF-α induced mitochondrial impairment observed in these cells. Indeed, overexpression of
miR-146a significantly reduces cellular bioenergetics (Jun et al., unpublished observation).
Additionally, TNF-α exposure caused a dose-dependent increase in both miR-34a and miR-146a
in secreted EVs. In line with other reports, these results suggest differential packaging and
secretion mechanisms which are dependent on specific miRNAs (Abels and Breakefield, 2016).
The results from the current study support the concept that some miRNAs (e.g. miR-34a) may be
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preferentially sorted out of cells (Jovičić and Gitler, 2017; Wei et al., 2017), however this
interpretation is strictly speculative and requires further investigation.

As TNF-α exposure significantly elevated miR-34a and miR-146a expression within secreted
EVs, we hypothesized that exposing naïve cells to TNF-α induced EVs would result in
significant reduction of mitochondrial respiration due to miRNA-mediated repression of ETC
protein translation. Interestingly, we observed significant increases in mitochondrial oxygen
consumption in naïve cells exposed to these vesicles. In this study, only relative changes in
miRNA expression were assessed, not definitive quantities. It has been postulated that there is
fewer than 1 copy of an individual miRNA per EV (Chevillet et al., 2014; Wei et al., 2017), so it
is likely that the absolute concentrations of miR-34a and miR-146a were not high enough to
induce physiologically relevant repression of ETC proteins in recipient cells and cause
reductions in oxygen consumption.

Several groups have also shown that exposure to EVs significantly increases mitochondrial
respiration in recipient cells (Phinney et al., 2015; Sansone et al., 2017; Bland et al., 2018), and
others have described that in response to stimulation, neurons are able to increase their rate of
glycolysis (Yellen, 2018). This unexpected increase in mitochondrial activity may actually be a
signal of mitochondrial stress, as we concomitantly observed dose-dependent increases in proton
leak, suggesting that although oxidative phosphorylation is increased, the mitochondria are not
actually functioning optimally. Indeed, a disproportionately large rate of mitochondrial oxygen
consumption likely indicates an attempt to maintain Ψm as proton leak across occurs (Jastroch et
al., 2010). Spare respiratory capacity is an indicator of mitochondria’s ability to respond to stress
(Hill et al., 2009). Here we observe significant elevation of spare capacity in cells exposed to
EVs, which is likely the mechanism by which mitochondria were able to maintain Ψm, despite
undergoing significant proton leak. As mitochondria are the main generators of ROS, it is likely
that the increased oxygen consumption incurred by maintaining Ψm is responsible for significant
ROS generation. Superoxide anions are quickly converted to less reactive H2O2 by superoxide
dismutases (Lennicke et al., 2015), which may explain why we saw significantly more H2O2 than
superoxide after EV exposure.
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Our observation of altered mitochondrial function after a single exposure to TNF-α, or TNF-α
induced EVs does not recapitulate the in vivo conditions of AD, as there is constant crosstalk
between different cell types, and persistent, dynamic EV-cell interactions. However, the current
findings suggest that neuronal, inflammation-derived EVs may acutely alter mitochondrial
activity in recipient cells. The mitochondrial cascade hypothesis of AD posits that increased ROS
induces mitochondrial DNA damage and reduces mitochondrial function; with time this initiates
a “reset response” in which Aβ production is increased, leading to further generation of ROS in a
vicious, positive feedback cycle (Swerdlow and Khan, 2004). While we have not identified the
cargo within EVs that initiates this mitochondrial response, future studies will address this issue,
as any component of EV-associated cargo may be responsible for these effects, e.g. direct
transfer of specific proteins, mRNAs, or other miRNAs not assessed here.

Importantly, the current study provides novel insights on the role of inflammation-induced EVs
in the inflamed and aging brain. The results underscore the importance of TNF-α, a canonical
proinflammatory cytokine in the brain, as a regulator of mitochondrial function, miRNA
expression, and EV secretion in neurons. Thus, TNF-α induced EVs may be drivers of the
bioenergetic function and dysfunction throughout the brain in AD and other neuroinflammatory
disorders.
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Figure Legends
Figure 3.1: TNF-α exposure significantly reduces cellular bioenergetic function and increases
cell death. After 24 hours exposure to TNF-α, basal respiration (A; F3,292 = 11.90, p < 0.001),
maximal respiration (B; F3,292 = 42.31, p < 0.0001), ATP production (C; F3,292 = 39.80, p <
0.0001), and spare capacity (D; F3,292 = 50.10, p < 0.0001) were significantly reduced at the
highest two concentrations. Proton leak (E; F3,202 = 10.62, p < 0.0001) was significantly
increased. Glycolysis was also significantly reduced after TNF-α exposure (F; F3, 164 = 59.42, p
< 0.0001). LDH data indicate that significant cell death occurred at all concentrations of TNF-α
exposure (G; F3,223 = 65.31, p < 0.0001). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
0.0001.
Figure 3.2: TNF-α exposure induces secretion of EVs. Particle size distributions calculated from
the NanoSight NS300 show expected size ranges for EVs (A; F3,3996 = 7.06, p < 0.0001).
Overall particle concentrations for each TNF-α exposure group indicate that TNF-α exposure
induces vesicle secretion (B). TNF-α induces EVs expressing canonical markers and are
appropriately sized. Canonical EV proteins and their locations on a dot blot are shown (C).
Presence of proteins expressed for control vesicles (C, top panel) and TNF-α (10 ng/ml) induced
vesicles (C, bottom panel) are shown. *p < 0.05, ****p < 0.0001.
Figure 3.3: TNF-α significantly alters miRNA expression profiles. TNF-α exposure did not
significantly alter intracellular expression of miR-34a (A; F3,32 = 1.29, p = 0.2951), but did
induce a dose-dependent increase in miR-34a expression within EVs (B; F3,31 = 30.00, p <
0.0001). Conversely, TNF-α exposure induced intracellular upregulation of miR-146a which
trended towards significance (C; F3,32 = 2.92, p = 0.0643), as well as a significant, dosedependent increases within EVs (D; F3,31 = 13.15, p < 0.0001). *p < 0.05, **p < 0.01, ***p <
0.001, and ****p < 0.0001.

Figure 3.4: Naïve cell EV uptake and functional consequences. EVs derived from control and all
concentrations of TNF-α (0, 0.1, 1, and 10 ng/ml) are taken up by naïve cells as evidenced by
punctate staining of red-labeled EV RNA present within naïve cells. Scale bar = 40 μm.
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Figure 3.5: TNF-α induced EVs (at all concentrations) significantly increased basal respiration
(A; F4,67 = 6.72, p = 0.0001) and maximal respiration (B; F4,67 = 15.05, p < 0.0001), while all
vesicles significantly increased ATP production (C; F4,67 = 3.64, p = 0.0096) and spare capacity
(D; F4,67 = 21.50, p < 0.0001). Proton leak was also significantly increased at the highest TNF-α
concentrations (E; F4,67 = 3.07, p = 0.0221). Exposure to these vesicles significantly increased
glycolysis as well (F; F4, 84 = 5.024, p < 0.0011). Significant cell death only occurred at the
highest concentration (G; F4,44 = 4.717, p = 0.003). *p < 0.05, **p < 0.01, and ***p < 0.001.
Figure 3.6: TNF-α induced EVs alter ROS production in recipient cells. EVs do not have a
significant impact on the inner mitochondrial membrane potential (A; F4,115 =1.287, p =
0.2794). Exposure of naïve cells to EVs significantly increases ROS production in the form of
mitochondrial superoxide (B; F4,113 = 2.787, p = 0.0298), and hydrogen peroxide (C; F4,85 =
5.329, p = 0.0007).
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4.1 Abstract
Stroke is a leading cause of death and disability in the United States. Traditional risk factors like
hypertension, diabetes, and obesity do not fully account for all stroke cases. Recent infection is
also now regarded as a stroke risk factor, as changes in systemic immune signaling can increase
risk of thrombosis formation. We have previously shown that administration of
lipopolysaccharide (LPS) 30 minutes prior to stroke induces significant increases in infarct
volume. In the current study, we assessed the effects of intermittent LPS exposure, with a long
recovery period, on stroke infarct volume. We found that animals repeatedly exposed to LPS
have significantly larger cortical infarcts when compared to saline controls. To elucidate the
mechanism behind this phenomenon, several avenues were investigated. We found significant
upregulation of TNF-α mRNA, especially in the ipsilateral hemisphere of both saline and LPS
exposed groups when compared to sham surgery animals. Further, we assessed expression of
genes involved in autophagy (Beclin-1, ATG5, LC3a, and LC3b) and observed significant
reduction in their expression in the ipsilateral hemisphere of the LPS stroke animals.
Transcription of several of these genes may be regulated by DNA methylation, which is
mediated by DNA methyltransferases (DNMTs). We assessed mRNA expression of DNMT1,
DNMT3a, and DNMT3b and observed a significant downregulation of DNMT1 and DNMT3a in
the ipsilateral hemisphere of LPS stroke animals, suggesting that changes in DNA methylation
occur in response to stroke after repeated LPS exposure.
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4.2 Introduction
Stroke is the fifth leading cause of death and a major cause of disability in the United States
(Yang et al., 2017). Traditionally recognized risk factors for stroke and other acute vascular
events include hypertension, diabetes, obesity, and tobacco use (Yang et al., 2017). In addition,
recent (7-10 days) bacterial or viral infections are also recognized as potential stroke risk factors
(Grau et al., 1995, 2005; Bova et al., 1996; Paganini-Hill et al., 2003). Systemic infection can
alter thrombosis formation by increasing platelet aggregation (Zeller et al., 2005; Elkind et al.,
2011) and increase circulating cytokine concentrations (Wilson et al., 1998; Guedes et al., 2016)
which have been shown to play a major role in fibronectin accumulation (Pawluczyk and Harris,
1998) and thereby contribute to thrombosis formation (Maurer et al., 2010). Additionally,
systemic inflammation can induce changes in endothelial cell function (Stern et al., 1988) which
may contribute to the development of atherosclerosis (Sessa et al., 2014; Campbell and
Rosenfeld, 2015).

Previous work from our laboratory has found that exposure to lipopolysaccharide (LPS) 30
minutes prior to experimental stroke significantly increases infarct volumes when compared to
vehicle injected controls (Doll et al., 2015b). In the current study, we sought to expand these
findings and determine if intermittent LPS exposure could be additive over time, increasing
infection burden of the organism, and lead to significantly larger stroke infarcts. In an effort to
mimic the rate of illness experienced by an adult human, we induced an immune response in
mice every two weeks (akin to ~2 years in a human), with ample time to fully recover between
insults. Despite animals being fully recovered from the last LPS injection at the time of surgery,
we observed a significant increase in infarct size in the LPS treated group when compared to the
saline controls. We further explored this finding by assessing changes in gene expression within
the ipsilateral and contralateral hemispheres of the brains.

4.3 Materials and Methods
Animals
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Twenty four male C57BL/6J mice (12 weeks of age) were acquired from Jackson Laboratory
(Bar Harbor, ME). Animals were housed in sterile micro-isolator cages with sterile bedding, and
provided food and water ad libitum in the West Virginia University Health Science Center
animal facility. All procedures were conducted according to criteria approved by the Institutional
Animal Care and Use Committees at West Virginia University.

Intermittent immune activation paradigm
Lipopolysaccharide (LPS; Escherichia coli 055:B5, Sigma, St. Louis, MO) was reconstituted in
sterile, injectable saline (B. Braun Medical Inc, Irvine, CA). Animals were administered LPS (or
an equal volume of saline) via intraperitoneal (i.p.) injection. To ensure that animals elicited an
immune response, the concentration of LPS was doubled with each subsequent injection. Each
injection was separated by a two-week recovery period to allow for animals’ health to return to
baseline levels (Figure 1).

Sickness behavior monitoring
To measure animals’ sickness behavior prior to, and after each LPS (or saline) injection, a 0-20
point scale of overall health was implemented (Doll et al., 2015a). For the majority of the health
screen, animals were observed in their home cage to assess behavior across several parameters,
including general appearance, posture, respiration, and spontaneous locomotion/social
interaction. Animals were removed from the cage to then assess their body condition,
temperature, and weight. A score was assigned for each parameter, which were then summed to
provide an overall assessment of the animal’s health.

Prior to the beginning of the injection paradigm, baseline health screen measurements were
obtained, which were then used for determining changes from the norm for each individual
animal. Four hours post-injection, the health screen was administered to ensure animals were
exhibiting a sickness response due to LPS exposure. Additionally, 13 days post-injection the
health screen was conducted to ensure animals recovered to baseline levels of health (Figure 1).

Transient middle cerebral artery occlusion and sham surgery
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Surgical anesthesia was induced with 4-5% isoflurane and maintained with 1-2% isoflurane via
face-mask in oxygen-enriched air. Transient middle cerebral artery occlusion (tMCAO) model
was performed with a 6.0 monofilament suture (Doccol, Sharon, Massachusetts) for seventy
minutes, with rectal body temperature maintained at 37°C ± 0.5°C during surgery with a warm
blanket (Stoelting Co, Wood Dale, IL). To confirm successful occlusion (>70% decrease in
blood flow), regional cerebral blood flow was detected using laser Doppler flowmetry (Moor
instruments, United Kingdom). All surgeries were performed by one surgeon who was blinded to
pre-treatments.

Exclusion criteria for animal experiments
Several exclusion criteria for tMCAO were implemented in this experiment, as we have
previously described (Doll et al., 2015b; Sun et al., 2016). (1) A decrease of regional cerebral
blood flow < 70% during occlusion as detected by laser Doppler flowmetry; (2) surgery time
lasting > 70 minutes; (3) neurological score 0, indicating no neurologic deficit 3 hours after
tMCAO; (4) no infarction in the MCA territory as indicated by TTC staining; (5) subarachnoid
hemorrhage upon post-mortem examination; (6) substantial ambient temperature changes in the
animal housing facility; and (7) body temperature at or below 32°C.

In this study, 3 mice were excluded: 1 mouse (saline treated) because the laser Doppler
flowmetry did not reach 70% reduction during the occlusion, and 2 mice (LPS treated) because
body temperatures were below 32°C.

Analysis of cerebral infarct volume
All animals were euthanized 24 hours post-ischemia via cardiac puncture. Animals were then
perfused with 1X phosphate buffered saline (PBS). Brain from 3 saline and 3 LPS animals were
submerged in formaldehyde for later histological confirmation of infarct (data not shown). The
remaining brains were removed and cut into 2-mm sections with a mouse brain matrix. Sections
were stained with 2% 2,3,5-triphenyltetrazolium chloride (TTC; Sigma, Saint Louis, Missouri) in
PBS solution at 37°C for 15 minutes, and digitally photographed.
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After imaging TTC stained brain slices, brain tissue was dissected into four groups. The main
infarcted tissue was dissected away from each of the slices and pooled together as the ipsilateral
core, while the remaining tissue from the ipsilateral hemisphere was pooled together as the
ipsilateral penumbra. Mirroring sections were taken from the contralateral hemisphere and
termed contralateral core and contralateral penumbra. Tissue was snap frozen in liquid nitrogen
and stored at -80°C. Each pooled sample was homogenized for later RNA analysis as an
independent sample.

Digitized images of each brain section were analyzed using computerized image analysis
software (ImagJ, NIH) in a blinded manner. Brain and infarct volumes for right (ipsilateral) and
left (contralateral) hemispheres were calculated. Volumes were calculated as a percentage of
contralateral cortex, striatum, and total hemisphere to reduce the effect of brain edema.

RNA isolation and PCR
Total RNA, including miRNAs, was isolated from brain tissue via Trizol extraction (Invitrogen).
500 μl Trizol was added to each sample and vortexed; 125 μl chloroform was next added to the
sample and vortexed. After a 10 minute incubation period on ice, samples were centrifuged at
15,000 rpm for 15 minutes at 4°C. The upper aqueous layer was transferred to a new microfuge
tube, followed by the addition of 500 μl isopropanol and 1 μl glycogen. The samples were stored
at -20°C for 24-48 hours to allow for RNA precipitation. The samples were centrifuged for 10
minutes at 15,000 rpm and washed twice with 200 μl of 75% ethanol. RNA was dried and
resuspended in 20 μl RNase free water.

RNA concentrations were measured with a NanoDrop One Microvolume UV-Vis
Spectrophotometer (ThermoFisher), and 1 μg was reverse transcribed using the SuperScriptTM
III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen) as per the manufacturer’s
instructions. Briefly, 10 μl 2X RT Reaction Mix, 2 μl RT Enzyme Mix, and 8 μl cDNA were
incubated at 25°C for 10 minutes, 50°C for 30 minutes, and 85°C for 5 minutes. 1 μl E. coli
RNase H was added to each sample, then incubated at 37°C for 20 minutes.
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Additionally, 1 μg total RNA containing microRNAs was reverse transcribed using the miScript
II RT kit (Qiagen) as per the manufacturer’s instructions. Briefly, 2 μl 5x miScript HiSpec
Buffer, 1 μl 10x miScript Nucleics Mix, 1 μl miScript Reverse Transcriptase Mix, and 6 μl
Template RNA/nuclease-free water were incubated at 37°C for 60 minutes and 95°C for 5
minutes. Predesigned PrimeTime qPCR primers for RPL4 and CAP-1 (internal controls), as well
as TNF-α, Beclin-1, ATG5, LC3a, LC3b, DNMT1, DNMT3a, and DNMT3b were purchased from
Integrated DNA Technologies (Coralville, IA).

Expression of miR-155, -181a, and -181c was assayed using target specific miScript primer
assays and the miScript SYBR® Green PCR kit (Qiagen) (5 μl SYBR® Green; 1 μl Universal
Primer; 1 μl Target Primer; 3 μl diluted cDNA) using the CFX384 Touch™ Real-Time PCR
Detection System (Bio-Rad, Hercules, CA, USA) for 45 cycles as follows: 15 sec at 94 °C, 30
sec at 55 °C, 30 sec at 70 °C. All miRNA specific primers were miScript Primer Assays
(Qiagen); Hs_RNU6-2_11 (MS00033740), and Hs_miR-155 (MS000031486); Hs_miR-181a
(MS00008827); and Hs_miR-181c (MS00008841). The expression levels of target genes were
standardized against RNU6.

Quantification of PCR amplified mRNA and microRNA specific cDNA was done by
comparative cycle threshold CT method (2-ΔΔCT). Two independent values were obtained for
each hemisphere (core and penumbra) for all animals. Fold changes of target gene expression in
the ipsilateral and contralateral hemispheres of saline or LPS exposed stroke animals was relative
to that of the corresponding hemisphere of the sham animals. cDNA could not be synthesized
from samples with low RNA yield (<1ug total RNA), and were excluded from analysis.
Significant outliers, as determined by GraphPad Prism 8.0, were excluded from analysis.

Statistical analyses
All quantitative data were assessed for significance using either a one-way ANOVA with
Dunnett’s post hoc test, or Student’s t test. All results were analyzed by GraphPad Prism 8.0
software (GraphPad Software, La Jolla, CA). Results from the experiments are reported as means
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± SEM. A p value < 0.05 was used to establish significance; significance presented as *p<0.05,
**p<0.01, ***p<0.001, and ****p<0.0001.

4.4 Results
LPS injections significantly alter animal health status
LPS exposure induces an acute sickness response, from which animals recovered (Figure 2).
Throughout the duration of the experiment, there were no significant changes in health screen
scores for animals exposed to saline; thus all health screen data for these animals was grouped
together. Animals exposed to LPS exhibited significant sickness behaviors four hours postinjection after injections 1, 2, and 4, while injection 5 trended towards significance. At 13 days
post-LPS, health screen scores averaged < 1, indicating that animals returned to normal health
status between injections.

Repeated LPS exposure significantly increases cortical infarct volume
By day 13-post injection 5, all animals exhibited a full behavioral recovery. Despite this, we
observed a significant increase in stroke infarct volume in animals that were intermittently
injected with LPS, compared to the saline-injected controls (Figure 3). There were significantly
larger infarct volumes in the cortex and total ipsilateral hemisphere in the LPS treated animals
compared to saline; however, there were no significant differences in striatal infarct volume
between the two groups (Figure 3B).
TNF-α mRNA transcription is significantly upregulated 24 hours post-stroke
Due to our findings that intermittent exposure to LPS significantly increased infarct size, we
sought to better understand the mechanism by which this effect was occurring. Tumor necrosis
factor-alpha (TNF-α) is a proinflammatory cytokine which is thought to play an important role in
the post-stroke immune response (Barone et al., 1997). We measured TNF-α mRNA in the
contralateral and ipsilateral hemispheres of saline or LPS-injected animals that underwent
tMCAO, as well as sham surgery controls (Figure 4). We found a significant increase in TNF-α
mRNA expression in both hemispheres of the animals subjected to tMCAO when compared to
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the sham surgery group. Interestingly, TNF-α mRNA expression increased in both saline and
LPS groups ~ 5-fold in the contralateral hemisphere (Figure 4A), while in the ipsilateral
hemisphere, TNF-α mRNA was increased ~ 50-fold in the saline group, but only ~ 35-fold in the
LPS group (Figure 4B).

LPS exposure significantly alters post-stroke autophagy-associated mRNAs
As changes in TNF-α mRNA expression did not appear to be the driving force leading to
increased infarct size after repeated LPS exposure, we examined expression of various genes
associated with autophagy. As shown in Figure 5, we observed significant reductions in all four
autophagy genes in the ipsilateral hemispheres of at 24-hours post-stroke in the LPS exposed
animals when compared to shams (Figure 5B, D, F, H). Beclin-1 was also significantly reduced
in both hemispheres of the saline exposed stroke animals when compared to sham (Figure 5A
and B).

Stroke alters miRNA profiles
Post-stroke alterations in gene expression, including that of microRNAs (miRNAs), has been
observed by many groups, (as reviewed by Sarkar et al., 2018). In the ipsilateral hemisphere, we
observed significant upregulation of miR-155 (Figure 5B) in both the saline and LPS treated
stroke animals, when compared to sham surgery controls. Significant downregulation of miR181a (Figure 5D) was observed in both stroke groups, while significant downregulation of miR181c (Figure 5F) was only observed in the LPS stroke group.

LPS exposure prior to stroke significantly reduces DNMT mRNA expression
De novo DNA methylation occurs via DNMT3a and DNMT3b, while DNMT1 functions to
maintain methylation (Okano et al., 1999). We assessed changes mRNA expression of these
DNMTs to indirectly assess the possibility of inflammation-induced changes in DNA
methylation. We observed a significant downregulation of DNMT1 mRNA expression in both
the contralateral (Figure 7A) and ipsilateral (Figure 7B) hemispheres of stroke animals exposed
to LPS when compared to sham controls. We also observed significant downregulation of
DNMT3a mRNA expression in the contralateral hemisphere (Figure 7C) of LPS exposed stroke
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animals, and downregulation in the ipsilateral hemispheres (Figure 7D) of both saline and LPS
exposed stroke animals. We observed no significant changes in DNMT3b expression (Figures 7E
and F).

4.5 Discussion
In this study, we found that intermittent immune activation with the gram-negative bacterial wall
component, LPS, induces significant sickness behaviors 4 hours post-injection, and that animals
recover from this effect in < 13 days. Despite making a full recovery after the last injection of
LPS, animals subjected to tMCAO had significantly larger infarct volumes at 24-hours
reperfusion when compared to saline injected animals. We investigated several avenues to
elucidate the mechanism behind this phenomenon. Consistent with the literature, we found
significant upregulation of TNF-α mRNA in the brains of stroke animals, when compared to
sham controls. We also assessed expression of autophagy related mRNAs and found significant
reductions in expression within the ipsilateral hemispheres of the LPS exposed stroke mice.
Reduced autophagic function can lead to the accumulation of damaged proteins and organelles
and lead to cellular apoptosis and necrosis. We next assessed changes in miRNAs previously
implicated in stroke which may be involved in reducing autophagy gene expression, as well as
DNMTs that may be altering the methylation status of the autophagy genes.

As infarct size is significantly increased after exposure to LPS, we sought to determine the
mechanism by which this occurs. At the transcriptional level, TNF-α mRNA is significantly
upregulated in post-stroke brains (Pan and Kastin, 2007), and protein expression in blood plasma
of stroke patients 24 hours post-insult has been positively correlated with infarct volume
(Zaremba and Losy, 2001). Administering exogenous TNF-α prior to experimental stroke
significantly exacerbates infarct volume, while blocking endogenous TNF-α signaling poststroke has shown to be neuroprotective (Barone et al., 1997). Previous work has also
demonstrated that systemic administration of LPS can induce TNF-α mRNA expression (Buttini
et al., 1997). Further, it is well established that systemic inflammation activates the sympathetic
nervous system (Pongratz and Straub, 2014), and can lead to enhanced transcription of TNF-α
90

mRNA within the brain (Zielinski et al., 2013). We hypothesized that our observation of LPSinduced increases in stroke infarct volume may be mediated by increased expression of TNF-α
24 hours post-stroke. Despite observing significant post-stroke upregulation of TNF-α mRNA
expression, we observed no significant differences in TNF-α mRNA expression between saline
and LPS exposed stroke animals, indicating that another mechanism is likely underlying this
phenomenon.

Although not significant, the saline exposed stroke animals expressed higher levels of TNF-α
mRNA (~ 50-fold) than the LPS exposed stroke animals (~ 35-fold). A recent study described an
interesting LPS-mediated effect of immune tolerance within the brain. Two consecutive
injections of LPS were required to initiate an immune response within the brain, however this
effect was attenuated by the fourth injection (Wendeln et al., 2018). We may have observed
reduced TNF-α mRNA in the LPS group, compared to the saline, due to immune tolerance, as
these animals already had several experiences with brain-immune activation, while the animals
injected with saline were experiencing a significant inflammatory event for the first time (i.e. the
stroke). We also observed attenuation of sickness behavior with each subsequent LPS exposure,
further strengthening the notion of LPS-tolerance after repeated exposure.
TNF-α signaling can activate the transcription factor NF-κB, leading to the activation of mTOR,
a prominent inhibitor of autophagy (Djavaheri-Mergny et al., 2006). We hypothesized that
chronic LPS exposure would significantly upregulate TNF-α expression and potentially inhibit
autophagy, leading to the promotion of apoptosis and necrosis, thus resulting in significantly
larger infarct sizes. While this may occur in the general pathology of stroke, there do not appear
to be significant differences in TNF-α expression between the saline and LPS exposed stroke
animals.

Autophagy is generally regarded as a self-protective mechanism, which breaks down and
recycles long-lived, damaged, or misfolded proteins and organelles (Wang et al., 2018b).
Oxygen and nutrient deprivation can activate autophagy, and several studies have found that
activation of autophagy during cerebral ischemia has neuroprotective benefits by degrading
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damaged structures and thereby limiting apoptosis (Wang et al., 2012; Papadakis et al., 2013).
We assessed mRNA expression of several genes involved in the autophagy pathway; Beclin-1,
ATG5, LC3a, and LC3b, which all have important functions in the formation and maturation of
the autophagosome (Wang et al., 2018b). If post-stroke autophagy is being inhibited in the
ipsilateral hemisphere of LPS exposed animals, damaged organelles and proteins are not being
degraded. The accumulation of such damaged cellular contents can trigger apoptosis, or induce
necrosis in these cells. This could contribute to the enlarged infarct we observed in the LPS
exposed animals.

We also assessed levels of miRNAs previously implicated in stroke. miRNAs are small (~22
nucleotides), non-coding RNAs that function as gene repressors by cleaving mRNAs, inhibiting
mRNA translation, or targeting mRNAs for degradation (Ha and Kim, 2014). Up or
downregulation of various miRNAs have been demonstrated to significantly impact stroke
outcome. We chose to assess three miRNAs that have been previously implicated in stroke,
including miR-155 (Caballero-Garrido et al., 2015; Pena-Philippides et al., 2016), miR-181a
(Ouyang et al., 2012; Hough et al., 2018), and miR-181c (Ma et al., 2016). Contrary to our
findings, several studies in the literature report observing increased post-stroke expression of
miR-181a and miR-181c, and describe their detrimental role in stroke neuropathology (Ouyang
et al., 2012; Ma et al., 2016; Hough et al., 2018). However, miR-181a (Zhu et al., 2017) and
miR-181c (Zhang et al., 2012) negatively regulate TNF-α expression. Reduced expression of
these miRNAs may allow for significant upregulation of TNF-α mRNA. TNF-α induces miR155 upregulation (Migita et al., 2017), and miR-155 targets several key players in autophagy
(Wang et al., 2018a), including ATG5 (D’Adamo et al., 2016) and beclin-1. We observed
significantly lower expression of miR-181a and -181c in the ipsilateral hemisphere of both the
saline and LPS exposed stroke groups when compared to sham controls, and we also observed a
striking increase in TNF-α mRNA in this region. Further, in the ipsilateral hemisphere, we
observe significant elevation of miR-155, which can be upregulated by TNF-α. As miR-155
targets several genes associated with autophagy, and we observe significant reductions in the
ipsilateral hemisphere of all four genes, a link between these molecules is emerging, potentially
leading to reduced autophagic functioning in the ipsilateral hemisphere of LPS exposed stroke
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animals. Utilizing miRNA overexpression or antagomir models would allow for more direct
manipulation of these pathways to better aid in understanding their role in stroke outcomes. In
addition, assessment of mRNA transcripts at the protein level would allow for direct
understanding of miRNA-mediated gene repression.

DNA methylation is an epigenetic modification that can be inherited, as well as influenced by
environmental factors. In recent years a growing interest in stroke-induced alterations of DNA
methylation has surfaced (Qureshi and Mehler, 2010; Soriano-Tárraga et al., 2014, 2017).
Segments (≥ 500 base pairs) of DNA which contain > 55% cytosine and guanine nucleotides can
be epigenetically modified via the methylation of cytosine residues. This mechanism is mediated
by DNA methyl transferases (DNMTs), and inhibits gene transcription by preventing
transcription factor binding (Krupinski et al., 2018). Aging, which is characterized by low-grade
chronic inflammation (Franceschi et al., 2018), is the main risk factor for stroke, and is
associated with global DNA hypomethylation (Johnson et al., 2012). Inflammation has also been
directly associated with changes in DNA methylation (Abu-Remaileh et al., 2015; Maiuri et al.,
2018). In animals chronically exposed to LPS, we observed significant downregulation of
DNMT1 and DNMT3a in the ischemic hemisphere post-stroke. This downregulation should
result in overexpression of numerous genes that have CpG islands. Future work should address
the methylation status of the genome after intermittent exposures to LPS alone, as well as poststroke.

In conclusion, this study has shown that chronic systemic inflammation induced by intermittent
injections of LPS can significantly increase cortical infarcts in an experimental stroke model. We
show that in the brain, TNF-α mRNA expression is significantly elevated post-stroke, regardless
of prior saline or LPS exposure. Further, we show that mRNA expression of autophagy genes is
significantly downregulated in the ischemic hemisphere of LPS exposed mice. We propose that
the mechanism by which significant increases in infarct volume occurs in the LPS exposed mice
is by de-regulated autophagy, leading to significantly increased neuronal apoptosis.
Alternatively, in view of our observation of a downregulation of DNMT mRNA expression in
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the ipsilateral hemisphere of LPS exposed stroke animals, we also propose that changes in DNA
methylation may also significantly contribute to increased infarct volume observed in this group.
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Figure Legends
Figure 4.1: Experimental timeline and study design. Prior to the start of the LPS (or saline)
injection paradigm, baseline health scores were obtained. Four hours post-injection, health screen
scores were measured to ensure animals exhibited sickness behaviors. To confirm recovery
between LPS exposures, thirteen days post-injection (i.e. one day prior to the next injection) the
health screen was again administered. LPS concentrations were doubled with each injection.
Thirteen days after injection 5, the health screen was administered once more to verify that
animals were no longer exhibiting sickness behavior. The following day, animals were subjected
to a 70 minute tMCAO surgery, followed by a 24-hour reperfusion period, at the conclusion of
which, animals were euthanized and tissues were collected.

Figure 4.2: LPS exposure induces an acute sickness response, from which animals recovered.
Health screen scores for animals exposed to saline were grouped together as they did not
significantly differ across time. There was a significant effect of LPS exposure on sickness
behavior when compared to saline injected animals (F10,157 = 12.69, p < 0.0001). Dunnett’s
post-hoc analysis indicated that when compared to saline-treated animals, animals exposed to
LPS exhibited significant sickness behavior four hours post-injections 1, 2, and 4, while injection
5 trended towards significance (p = 0.0667). Further, health sickness scores at the 13 day time
point did not significantly differ from those in the saline-injected group, indicating that animals
returned to normal health status. Data are expressed as mean ± SEM; one-way ANOVA. **p <
0.01 and ****p < 0.0001.

Figure 4.3: Repeated LPS exposure significantly increases stroke infarct volume. A.
Representative TTC stained coronal slices used to analyze infarct volume 24 hours post-stroke.
B. Animals repeatedly exposed to LPS had significantly larger infarct volume than saline
exposed mice in cortex and total hemisphere. Data are expressed as mean ± SEM; brackets
connect statistically significant groups; Student t test. *p < 0.05.
Figure 4.4: Stroke induces significant upregulation of TNF-α mRNA expression across the entire
brain. A. Compared to sham animals, TNF-α mRNA was significantly upregulated in the
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contralateral hemisphere of animals subjected to a 70 minute tMCAO, regardless of prior saline
or LPS exposure (F2, 25 = 28.33, p < 0.0001). B. Similarly, expression of TNF-α mRNA was
significantly upregulated in the ipsilateral hemisphere of animals subjected to a 70 minute
tMCAO when compared to sham (F2, 31 = 14.92, p < 0.0001). Data are expressed as mean ±
SEM; brackets connect statistically significant groups;**p < 0.01 and ****p < 0.0001.

Figure 4.5: Autophagy-related genes are downregulated in the ipsilateral hemisphere of LPS
exposed stroke animals. A. In the contralateral hemisphere, only saline injected animals had a
significant reduction in Beclin-1 mRNA expression when compared to sham controls (F2, 26 =
4.644, p = 0.0189). B. Both saline and LPS injected animals expressed significantly lower levels
of Beclin-1 in the ipsilateral hemisphere when compared to sham controls (F2, 31 = 5.457, p <
0.0093). In the contralateral hemisphere, no significant differences in (C) ATG5, (E) LC3a, or
(G) LC3b mRNA expression were observed. In the ipsilateral hemisphere, significant
downregulation of (D) ATG5 (F2, 31 = 3.972, p = 0.0291), (F) LC3a (F2, 31 = 3.393, p =
0.0465), and (H) LC3b mRNA expression was observed in the LPS exposed stroke animals when
compared to sham controls. Data are expressed as mean ± SEM; brackets connect statistically
significant groups; *p < 0.05.

Figure 4.6: miRNA expression is altered 24-hours post-stroke. In the contralateral hemisphere,
no significant changes in (A) miR-155, (C) miR-181a, or (E) miR-181c were observed. In the
ipsilateral hemisphere, there was significant upregulation of (B) miR-155 (F2, 28 = 11.82, p =
0.0002), and downregulation of (D) miR-181a (F2, 30 = 10.03, p = 0.0005) in both saline and
LPS treated stroke animals, when compared to sham controls. Significant downregulation of (F)
miR-181c (F2, 29 = 5.032, p = 0.0133) was observed only in the LPS treated animals when
compared to sham controls. Data are expressed as mean ± SEM; brackets connect statistically
significant groups; *p < 0.05, **p < 0.01 and ***p < 0.001.

Figure 4.7: DNMT mRNA expression is reduced post-stroke. DNMT1 mRNA expression was
significantly reduced in both the (A) contralateral (F2, 26 = 6.713, p = 0.0045) and (B) ipsilateral
(F2, 30 = 10.02, p = 0.0005) hemispheres of the LPS exposed stroke animals, when compared to
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sham controls. Similarly, DNMT3a mRNA expression was significantly reduced in the (C)
contralateral hemisphere of LPS stroke animals (F2, 26 = 4.388, p = 0.0228), and in the (D)
ipsilateral hemisphere of both saline and LPS stroke animals (F2, 30 = 9.661, p = 0.0006). No
significant changes in DNMT3b mRNA expression were observed (E, F). Data are expressed as
mean ± SEM; brackets connect statistically significant groups; **p < 0.01, ***p < 0.001, and
****p < 0.0001.
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Figure 4.1
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5. Discussion
The immune and nervous systems are both very complex networks. Elucidating the numerous
mechanisms that influence their crosstalk will undoubtedly assist in unveiling the etiology and
pathophysiology of various diseases, including that of AD and stroke. Discovery of viable
treatments and cures for such ailments is indeed on the horizon, as science and technology
converge and provide researchers with more information and experimental techniques than ever
before. In this dissertation, I have focused on the inflammatory mediators, TNF-α and LPS, and
their role in inflammatory processes in the brain, with a focus on EV production, miRNA
expression, mitochondrial dysfunction, and autophagy.
Through this body of work, I have found that direct exposure of TNF-α and LPS significantly
alters the expression of miRNAs associated with mitochondrial dysfunction (miR-146a and miR34a) in a variety of CNS-related cell types. Indeed, overexpression of miR-146a significantly
reduces cellular bioenergetic functioning, as does overexpression of miR-34a (Sarkar et al.,
2016). Further, stimulation of cells with TNF-α or LPS significantly alters EV secretion and
cargo, indicating that the communicative signaling packages (i.e. EVs) released by these
stimulated cells are modified as a direct result of their environment. Additionally, EV uptake
significantly alters recipient cell bioenergetics. Lastly, intermittent systemic exposure to LPS
significantly increases stroke cortical infarct volume at 13 day post-stroke. After assessing
expression of several mRNAs and miRNAs, we believe this effect is mediated through
downregulation of autophagy and changes in DNA methylation.

Inflammatory stimuli, EVs, and miRNAs
Inflammation significantly alters EV secretion and miRNA expression profiles in various CNS
cell types. Our studies indicate that 24-hours of TNF-α exposure significantly increases EV
secretion from neurons. Several recent papers report similar findings after TNF-α exposure in
astrocytes (Wang et al., 2017a; Chaudhuri et al., 2018) and brain endothelial cells (Dozio and
Sanchez, 2017). Others have reported significant changes to EV profiles post-inflammatory
insult (Yang et al., 2018), and it has been shown that EVs can mediate an immune response
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(Buzas et al., 2014). It is very likely that this secretory event occurring after exposure to an
inflammatory stimulus is the first step in a mechanism by which cells signal to their neighbors
that something is amiss, with EV-cell interaction being the next step in the process.

Previous work has shown that the EV-mediated transfer of miRNAs can alter protein expression
in recipient cells. As such, we also assessed changes in miRNA expression post-insult, both
within cells and their secreted EVs, and found that inflammatory stimuli significantly increase
expression of miR-34a and miR-146a.

Some intriguing observations have been made regarding intracellular vs EV RNA profiles which
warrant further introspection. It has been shown that larger EVs appear to have RNA profiles
which more closely mirror the parent cells from which they are derived, while smaller EVs differ
significantly from their cognate cells (Wei et al., 2017). As large EVs inherently have more
luminal space, they may be predisposed to contain more molecules representative of the parent
cell. On the other hand, small EVs have limited space, and may not be able to house many of the
molecules found in their parent cells. Conversely, several groups have posited that differences in
EV and cell RNA profiles represent differential sorting and secretion mechanisms, based on
RNA sequence (Abels and Breakefield, 2016; Wei et al., 2017). Data from our studies provide
evidence to support the notion of specific sorting mechanisms, however our data also suggest
that this may rely on the cell and stimulus type.
Neuronal exposure to TNF-α for 24 hours does not alter intracellular expression of miR-34a,
however there is a dose-dependent, significant increase in miR-34a expression in secreted EVs.
Conversely, the same treatment conditions induced significant intracellular upregulation of miR146a, which appeared to reach a ceiling threshold, after which it was secreted in EVs in a dosedependent manner. We also present similar data in primary neurons exposed to increasing
concentrations of Aβ; again, intracellular levels of miR-146a appear to reach a ceiling threshold,
at which point it is then secreted in EVs. Initial interpretation of these data are in support of the
concept that one miRNA, miR-146a, may rely on stochastic sorting mechanisms based on
concentration and distribution throughout the cell, while another, miR-34a, may be preferentially
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secreted from cells upon its synthesis, perhaps to act as an intercellular signaling molecule. To
complicate this idea however, we also have data from TNF-α exposed brain endothelial cells
indicating that intracellular miR-146a levels are significantly reduced post-exposure, yet
significantly increased in secreted EVs. However, when these cells are exposed to LPS, miR146a expression is significantly increased, both intracellularly and in secreted EVs. It is plausible
that miRNA expression and sorting mechanisms may be activated in both cell and stimulus-type
specific fashions. Determining whether or not these sorting mechanisms exist, if they are
differentially affected by varying stimuli, and the cell specificity of this effect are areas of
ongoing research in the EV field (Cha et al., 2015; McKenzie et al., 2016; Hinger et al., 2018).
Our studies indicate that both LPS and TNF-α exposure significantly increase the expression of
miR-34a and miR-146a in vitro in various cell types of the CNS. Because of the proinflammatory cascade initiated by oxygen-glucose deprivation, we also assessed expression of
these miRNAs in the brains of our sham and stroke animals. Interestingly, we found no
significant changes in expression of either miRNA post-stroke (Figure A1). These data further
indicate that miRNA expression may be heavily stimulus and context specific.

The importance of cellular-specific RNA expression
Knowing the cellular source of miRNA expression in tissue is also an important consideration
for discussion. For example, miR-155 is significantly upregulated in the ischemic hemisphere of
post-stroke LPS exposed animals. In neurons and their secreted EVs, TNF-α exposure
significantly increases miR-155 expression in a pattern similar to that of miR-146a expression
(Figure A2). Because expression of miRNAs in our animal studies was performed with whole
brain tissue, we cannot accurately determine the source of miR-155. Other cell types, including
microglia (Cardoso et al., 2012; Yin et al., 2017), have been shown to release miR-155 in
response to inflammatory stimuli (Alexander et al., 2015).

A viable approach for determining cell-specific miRNA expression from tissue is to utilize
fluorescence-activated cell sorting (FACS). By labeling neuron, microglial, astrocytic, and
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endothelial cell specific markers, we could sort tissue homogenates into cell-specific populations
for downstream miRNA assessment (Guez-Barber et al., 2012). From this, we could determine
the specific cell types implicated in disease pathogenesis.

The importance of cell-type determination of RNA expression can also be discussed in the
context of mRNAs. We assessed expression of the autophagy genes Beclin-1, ATG5, LC3a, and
LC3b, at the tissue level in sham and stroke animals. Significant downregulation of these genes
was observed in the ischemic hemisphere of the LPS exposed animals, however we do not know
which cells are being affected by the potential downregulation of autophagy. During ischemia,
neurons are deprived of oxygen and glucose, and mitochondrial dysfunction occurs. Mitophagy
is a quality control process by which damaged or stressed mitochondria are degraded via
autophagy (Ding and Yin, 2012). This process has been implicated in the pathogenesis of stroke
(Tang et al., 2016; Guan et al., 2018). Administration of the autophagy activator rapamycin,
significantly increased mitophagic activity after stroke, and significantly reduced infarct volume
(Li et al., 2014). Due to our observation of downregulated autophagy genes in the LPS exposed
stroke animals, we believe that the significantly larger infarct volumes exhibited in this group
may be due to reductions in autophagic capacity, specifically mitophagy. Downregulation of this
pathway will lead to accumulation of damaged and stressed mitochondria, with subsequent
release of cyt c into the cytosol, thus triggering apoptosis (Hara et al., 1997; Liang et al., 2013).

However, due to the utilization of whole-tissue samples, as opposed to cell-specific analysis, we
cannot definitively ascertain which cell type autophagy is downregulated in. Is this a whole-brain
issue, occurring within all CNS cell types, or does it only occur in specific cells? Most
commonly studied in this context are neurons, however microglia may also be negatively
impacted by reductions in autophagy. Although the role of microglial autophagy in ischemia is
unknown (Plaza-Zabala et al., 2017), a recent study suggests that inhibition of this process may
over-sensitize microglia and cause an over-activation of the proinflammatory response (Ye et al.,
2017). If our observations of downregulated autophagy genes are predominately occurring in
microglia, the subsequent increases in infarct size we may actually be a result of enhanced
inflammation, not direct cell death incurred from inhibited autophagy in neurons. For
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understanding the pathophysiology of autophagy in stroke, it would be very informative to
delineate exactly which cell types may be experiencing autophagic downregulation.

There is a large push in the EV field to utilize these small, lipid bound vesicles as therapeutic
agents for drug delivery (Di Rocco et al., 2016; Vader et al., 2016; Lv et al., 2018). As EVs can
cross the BBB, there is great interest in utilizing designer EVs to deliver therapeutic molecules to
the brain (Neubert and Glumm, 2016; Krämer-Albers, 2017; Rufino-Ramos et al., 2017).
Additionally, some groups are working to create EVs that can target cells specifically, based on
specific protein markers on the EV and cell surface (Antes et al., 2018). If these types of
treatments become a reality, it is plausible that EVs could be engineered to specifically target
subsets of cells for delivery of therapeutic agents. In light of the discussion above, knowledge of
the cell-source from which altered RNA expression is stemming would greatly aid in designing
safe and effective EV-delivery therapies. For example, if autophagy was downregulated
specifically in microglia, and not neurons, adoptive transfer of microglia-targeted-EVs
containing mRNAs of the endogenously downregulated proteins (or the proteins themselves)
could rescue autophagy, and reduce the exaggerated pro-inflammatory phenotype. Incorrectly
targeting these EVs to neurons instead of microglia could result in over activation of autophagy
in these cells and exacerbate cell death even further (Liu and Levine, 2015). Conducting
experiments assessing gene expression changes at the cell-level are significantly more
informative than those at the tissue level, and will provide better insight for the future
development of therapeutic agents.

miR-146a and Mitochondrial Function
In our studies, we found that neural exposure to the cytokine TNF-α induces significant
reductions in oxidative phosphorylation and glycolysis, which may be due to significant cell
death. However, downregulation of cellular bioenergetic function may be due, in part, to the
increased intracellular expression of miR-146a. The potential mitochondrial electron transport
chain (ETC) targets of miR-146a include: NADH-ubiquinone oxidoreductase chain 1, NADH
dehydrogenase 2, NADH dehydrogenase subunit 4, NADH:Ubiquinone Oxidoreductase Core
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Subunit 5, NADH:Ubiquinone Oxidoreductase Core Subunit 6, ATP Synthase Membrane
Subunit 8, as well as phosphoglycolate phosphatase (PGK1) which is involved in glycolysis. In
these studies, we have also shown that overexpression miR-146a significantly reduces oxidative
phosphorylation and glycolysis in primary microglia. The ETC mRNA targets described above
are all encoded by mitochondrial DNA (as opposed to being nuclear encoded), therefore, these
mRNAs should be constitutively expressed in neural cells as well. Although we did not directly
examine the effects of miR-146a overexpression in neural cells, it is likely that we would
observe similar significant reductions in oxidative phosphorylation, as shown in microglia.

We have also shown that miR-146a expression is positively correlated with AD pathology,
specifically amyloid angiopathy. Mitochondrial dysfunction leads to increases in APP processing
towards the amyloidogenic pathway (i.e. producing Aβ42) (Gabuzda et al., 1994; Atamna and
Frey, 2007; Swerdlow et al., 2014). Upregulation of miR-146a in the AD brain leads has been
mechanistically linked to hyperphosphorylation of tau (Wang et al., 2016), which is the basis of
Braak & Braak staging of AD (Braak and Braak, 1991b). Our data also show a positive
correlation between miR-146a expression and Braak & Braak staging. Together, these data
suggest that inflammation-induced expression of miR-146a is highly pathological and in part,
mediates mitochondrial dysfunction occurring within AD and as such, this miRNA may be a
potential therapeutic target in AD.

EVs have been shown to contain functionally active proteins, RNA, and DNA, which can exert
functions in recipient cells. As such, studying how their internal cargo affects recipient cells
upon uptake is an exciting area of research (Baj-Krzyworzeka et al., 2002; Lotvall and Valadi,
2007; Raposo and Stoorvogel, 2013). As neural communication is one of the basic tenants of
cognition, it is surprising how few groups focus on neuron-to-neuron communication via EVs.
We were interested in determining the effects of cytokine-induced neuronal-derived EVs on
naïve recipient neurons. Our observation of significantly elevated expression of miR-146a and 34a prompted the hypothesis that EV-uptake would induce significant mitochondrial and
glycolytic dysfunction in recipient cells.
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Exposing cells to TNF-α induced EVs actually resulted in significant upregulation of oxidative
phosphorylation with a concurrent increases in ROS. The 10 ng/ml TNF-α induced EV group
displayed the highest amount of peroxide generation (and a non-significant increase in
superoxide). Therefore, it is plausible that the significant amount of cell death observed in this
group may be mediated by cytochrome c (cyt c). miR-146a and miR-34a downregulates
expression of B-cell lymphoma 2 (Bcl-2), which is an anti-apoptotic protein which resides in the
mitochondrial outer membrane (Rippo et al., 2014). Downregulation of Bcl-2 augments ROS
formation (Zimmermann et al., 2007; Uraoka et al., 2011), and can contribute to loss of the
mitochondrial membrane potential (Wang and Welsh, 2014). Although we did not observe
significant loss of membrane potential, measurements of this parameter were highly variable
only in cells exposed to EVs (control group was less variable). Additionally, proton leak was
significantly elevated, likely in an attempt to maintain membrane potential. It is possible that
EV-mediated transfer of miR-146a and miR-34a was affecting these cells via the downregulation
of Bcl-2, and subsequent alterations of mitochondrial membrane potential.

In these experiments, we induced the production of neuronal-derived EVs via acute exposure to
an inflammatory stimulus. In turn, recipient cells were acutely exposed to these EVs, and
although they produced significant amounts of ROS as a result, we did not observe significant
downregulation of oxidative phosphorylation as we had anticipated. However, chronic
inflammation is characterized by the persistent presence of inflammatory stimuli. Therefore, in
states of chronic exposure, transcription of NFκB dependent miRNAs may occur more
consistently. Further, chronic inflammation may also induce persistent EV secretion, and due to
elevated miRNA transcription, resultant EVs may contain higher copy numbers of these
miRNAs. As such, persistent exposure to EVs induced by persistent inflammatory stimuli more
accurately recapitulate what is occurring in the inflamed brain. Time-course studies in which
cells are repeatedly exposed to inflammatory stimuli, or inflammation-induced EVs would be
interesting endeavors to pursue, as they would more accurately recapitulate what is occurring in
vivo.
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Systemic Inflammation and Stroke Outcome
Our in vivo studies provide novel insights by which intermittent systemic inflammation can
significantly alter gene expression within the brain, and subsequently, stroke outcome. At 13
days post-recovery, animals intermittently exposed to LPS had significantly larger infarcts than
those exposed to saline. Further, these animals experienced significant reductions in mRNA
expression of autophagy and DNMT genes. These data suggest that even during periods of
perceived health, infection burden may be heavily weighing on the ability to respond to a
negative immunological insult, such as a stroke, by changing the epigenetic landscape.

Although many stroke risk factors have been identified, with recent infection being one of them,
the full contribution of each to onset of stroke remains unknown. Some evidence suggests that
ischemic preconditioning prior to stroke can reduce negative stroke outcomes by inducing
tolerance and augmentation of cellular survival mechanisms (Koch and Gonzalez, 2013).
Additionally, others have shown that systemic preconditioning via immune activation with the
TLR4 agonist, LPS, 48 hours prior to experimental stroke significantly reduces infarct volume
and suppresses neutrophil infiltration to the brain (Rosenzweig et al., 2004). Similar results were
obtained when low-doses of LPS (0.05 – 0.2 mg/kg) were chronically administered for three
consecutive days prior to stroke (Rosenzweig et al., 2007). It appears that most LPS
preconditioning studies utilize short-term paradigms. Indeed, the neuroprotective effects appear
to only be relevant if LPS is administered within 1-7 days of experimental stroke (Stevens et al.,
2008). In line with this, previous work from our laboratory demonstrated that administration of
LPS 30 minutes prior to experimental stroke significantly exacerbated stroke infarct volume
(Doll et al., 2015b). We present here our novel findings of intermittent LPS exposure on stroke
infarct volume, which is more reflective of the infection burden experienced by a human; most
humans do not only experience one illness during their lifetime, nor do they usually experience
all of them over the course of several days.
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LPS tolerance has been studied for decades, however the mechanism by which it occurs has yet
to be elucidated (López-Collazo and del Fresno, 2013). Data from our health screen assessment
confer that systemic tolerance was achieved with repeated LPS exposure, as sickness behavior
scores diminished with each injection. However, our infarct data are in strict contrast to much of
the previously published LPS tolerance/preconditioning work.
Interestingly, TNF-α has been implicated in LPS preconditioning. After three days of low-dose
systemic exposure to LPS, plasma TNF-α was significantly downregulated, as was TNFR1 in the
cortex of the LPS exposed animals (Rosenzweig et al., 2007). Although we did not assess these
parameters in our study, we did observe lower levels of TNF-α mRNA expression in the brains
of LPS exposed stroke mice when compared to saline (although this was not statistically
significant). If TNFR1 is indeed downregulated in the cortices of LPS exposed animals, this may
explain why we observed lower expression levels of TNF-α mRNA. As TNFR1 signaling
activates NF-κB, transcription of pro-inflammatory cytokines, including TNF-α, is induced. This
may create a positive feedback cycle; however if TNFR1 is downregulated, this cycling is
blunted and less TNF-α expression is observed as a result.

Understanding how systemic immune activation can influence the pathophysiology of stroke is
of great clinical relevance. In the current study, we utilized a bacterial mimetic, LPS to induce an
immune response. The majority of stroke patients are elderly, and people over the age of 65 tend
to experience more viral than bacterial infections (Leng and Goldstein, 2010). This may be due,
in part, to the slow rate of bacterial mutation, which allows individuals to build immunity
towards a greater number of bacterial pathogens throughout their lifespan. Viruses on the other
hand, mutate rapidly, and the elderly typically have less-effective immune responses, making
them more susceptible to viral infections (Leng and Goldstein, 2010). To be more clinically
relevant, future studies could induce an immune response with polyinosinic:polycytidylic acid
(poly I:C) to mimic a viral infection. In our immune activation paradigm, we induced a very mild
sickness, from which animals were able to recover. This was akin to a human experiencing a
mild cold about once every two years. If the number of times a person catches a cold throughout
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their lifetime significantly impacts the pathophysiology of stroke, we as a society need to rethink the way we view illnesses.

As we observed significant changes in gene expression, it is highly likely that other genes not
measured in this experiment were also altered in the LPS exposed stroke animals. Further
investigation is warranted here, as we did not assess changes in gene expression in a LPS-sham
group of animals. Additionally, as we observed downregulation of DNMTs, it is also possible
that changes in DNA methylation have occurred in the LPS exposed stroke animals. Acetylation
of histones prevents DNA transcription; inflammation has been shown to reduce acetylation and
allow for aberrant expression of normally repressed genes (Khangura et al., 2017). Although not
assessed in the current study, this type of epigenetic modification may also have played a role in
exacerbating infarct volumes in the LPS exposed stroke animals. Again, assessment of these
parameters in LPS-sham animals is necessary to obtain a better understanding of the mechanisms
at play here. We cannot say for certain that LPS alone has triggered these changes in gene
expression, as these alterations may be a combinatorial result of intermittent LPS exposure and
stroke.

Inflammation and Systemically Circulating EVs
Recent evidence suggests that both systemic and nervous system inflammation alter circulating
EVs, and these EVs can exert immunologic effects on recipient cells/organisms. Monocytedifferentiated macrophages were exposed to EVs isolated from the serum of acute stroke
patients; after a four-hour exposure period, macrophages incubated with stroke patient EVs were
activated, and TNF-α mRNA was significantly upregulated (Couch et al., 2017a).
Experimentally induced inflammation via peripheral LPS challenge significantly increased
circulating EVs (Li et al., 2018). These vesicles did not express endotoxin, but when injected
into naïve animals, were able to induce neuroinflammation as evidenced by elevated microglial
activation, astrogliosis, increased pro-inflammatory cytokine expression, and significant
upregulation of miR-155 (Li et al., 2018). In a similar experiment, CNS injury was induced by
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striatal injection of IL-1B, followed by isolation of circulating EVs (Couch et al., 2017b). These
EVs were then injected into naïve animals, which subsequently expressed sickness behavior and
upregulated expression of TNF-α mRNA in the periphery (Couch et al., 2017b). Together, these
data suggest that inflammation significantly alters EV concentrations, and these EVs have the
capacity to significantly alter health status, and likely contribute to the immune response.

We evaluated the circulating plasma EV profile of animals intermittently injected with LPS or
saline 24 hours post-stroke, as well as profiles from sham surgery animals (Figure A3).
Surprisingly, we found that stroke significantly reduced EV concentrations when compared to
sham controls (Figure A3A). We also made an interesting observation, noting that there were
significant differences in EV concentrations between the saline and LPS injected stroked
animals, with LPS injected animals having significantly higher concentrations of EVs than the
saline animals. EV size distributions were also significantly affected by stroke (Figure A3B);
sham animal EVs were mostly concentrated at 150 nm, while stroke EVs were more
concentrated between 200-350 nm. Differences in EV diameter may represent varying EV
populations, as exosomes are believed to be ≤ 150 nm, and MVs can be up to 1,000 nm. It is
possible that stroke reduces the amount of bona fide exosomes released into circulation, and
enhances membrane shedding of MVs.

Our data are in direct opposition of the previous studies detailed above in which LPS and stroke
increase circulating EV concentrations. An important caveat to point out is that the above
mentioned studies isolated EVs from serum, while we utilized plasma. To isolate serum, blood
must first be allowed to clot. During this process, platelets secrete substantial amounts of EVs
(Gemmell et al., 1993) which may constitute over half of all EVs detected in a serum preparation
(Witwer et al., 2013). Indeed, thrombogenic activators have been shown to be extremely potent
inducers of platelet-EV secretion (Aatonen et al., 2014, 2017). Additionally, platelets are
activated post-stroke (Marquardt et al., 2002; Cevik et al., 2016). The combination of these two
factors (thrombogenic activation and ischemic stroke) may significantly increase EV
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concentrations, post-blood collection. As such, plasma is the preferred fluid for EV isolation
from blood (Witwer et al., 2013), and may serve as a more accurate representation of circulating
blood EV profiles.

An additional confounding factor that differentiates our study from the two stroke studies
described above are that mice do not spontaneously experience strokes, they must be
experimentally induced. Stroke risk factors like hypertension (Erne et al., 1985), smoking
(Erikssen et al., 1977; Ghahremanfard et al., 2015), diet (McEwen, 2014), and weight (Santilli et
al., 2012) have been shown to influence platelet number, adhesiveness, and microparticle (i.e.
EV) secretion. If all of these variables increase, and activate platelets, these patients may have
significantly elevated levels of platelet-derived circulating EVs to begin with. After the ischemic
event, and after coagulation occurs for serum isolation, these concentrations may rise
substantially.

Regardless of the discrepancies in EV concentrations, an intriguing follow-up experiment would
be to isolate EVs from four groups of animals (intermittent LPS, intermittent saline, intermittent
LPS + stroke, intermittent saline + stroke) and tease out the effects of chronic immune activation
vs. stroke on circulating EV concentrations. Further, we could then inject naïve animals with
these EVs to determine how these EVs affect sickness behavior, systemic inflammation, and
neuroinflammation in the recipient animals. As EVs are postulated to cross the BBB (Matsumoto
et al., 2018), we could also assay the effects of these isolated EVs on microglia and neurons in
vitro, and examine their potential inflammatory effects.

Summary
My dissertation provides novel data demonstrating that various inflammatory stimuli (LPS, TNFα, and Aβ) significantly alter miR-146a expression in the secreted EVs of neurons, microglia,
and brain endothelial cells. We also show that overexpression of this miRNA significantly
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downregulates mitochondrial function, which may underlie mitochondrial dysfunction observed
in neuroinflammatory diseases. Further, we describe an understudied mechanism by which
neuron-to-neuron communication occurs during periods of inflammation, and for the first time,
provide data on the functional outcomes of neural uptake of inflammation-induced EVs on
cellular bioenergetics. In vivo evidence from our animal studies suggest that intermittent
systemic LPS exposure significantly increases stroke infarct size. The underlying mechanisms by
which this phenomenon occurs are likely related to downregulation of autophagy or changes in
DNA methylation. Together, these data suggest that inflammation is a powerful modulator of
genetic alterations within the brain.
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Appendix
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Figure A1. Post-stroke expression of miR-34a and miR-146a. There are no significant changes in
miR-34a expression in the (A) contralateral or (B) ipsilateral hemisphere. Similarly, there are no
significant changes in miR-146a expression in the (A) contralateral or (B) ipsilateral hemisphere.
Data are expressed as mean ± SEM.
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Figure A2. Intracellular and EV miR-155 expression. HT-22 cells were exposed to TNF-α for 24
hours and expression of miR-155 was profiled both intracellularly and within the secreted EVs.
Intracellular expression was significantly elevated in all TNF-α exposure groups (A; F3,31 =
7.504, p = 0.0006). EV miR-155 expression was significantly elevated at the two highest TNF-α
exposures (B; F3, 31 = 8.762, p = 0.0002). Data are expressed as mean ± SEM; brackets connect
statistically significant groups; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Figure A3. Post-stroke plasma EV concentrations. EVs were isolated from the plasma of stroke
animals at 24 hours reperfusion. Stroke surgery significantly reduced circulating plasma EV
concentrations (A; F2, 2997 = 31.34, p < 0.0001). Dunnett’s post-hoc analysis significantly
indicated that there was a significant difference in EV concentration between saline and LPS
treated animals, with LPS animals having significantly higher circulating levels. Stroke also
substantially altered the size distribution profiles of EVs (B). Sham animal EVs were mostly
concentrated at 150 nm, while stroke EVs were more concentrated between 200-350 nm. Data
are expressed as mean ± SEM; brackets connect statistically significant groups; **p < 0.01,
****p < 0.0001.
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